---
document_datetime: 2023-09-21 17:40:07
document_pages: 45
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/isentress-h-c-860-x-0024-g-epar-assessment-report-extension_en.pdf
document_name: isentress-h-c-860-x-0024-g-epar-assessment-report-extension_en.pdf
version: success
processing_time: 35.0265498
conversion_datetime: 2025-12-21 19:00:00.387522
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

13 December 2012 EMA/CHMP/16343/2013 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Isentress

International non-proprietary name: raltegravir

Procedure No. EMEA/H/C/000860/X/0024/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:                 | Isentress                                                                                                                                                                                                             |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                     | Merck Sharp & Dohme Ltd. Hertford Road Hoddesdon, Herts EN11 9BU United Kingdom                                                                                                                                       |
| Active substance:                              | raltegravir                                                                                                                                                                                                           |
| International Nonproprietary Name/Common Name: | raltegravir                                                                                                                                                                                                           |
| Pharmaco-therapeutic group (ATC Code):         | Other antivirals (J05AX08)                                                                                                                                                                                            |
| Therapeutic indication(s):                     | ISENTRESS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 2 years. |
| Pharmaceutical form:                           | Chewable tablet                                                                                                                                                                                                       |
| Strengths:                                     | 25 and 100 mg                                                                                                                                                                                                         |
| Route of administration:                       | Oral use                                                                                                                                                                                                              |
| Packaging:                                     | bottle (HDPE)                                                                                                                                                                                                         |
| Package size:                                  | 60 tablets                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                        |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6       |                                                                                                        |
| 1.2. Manufacturers......................................................................................................7   |                                                                                                        |
| 1.3. Steps taken for the assessment of the product.........................................................7                |                                                                                                        |
| 2. Scientific discussion                                                                                                    | ................................................................................8                      |
| 2.1. Introduction.........................................................................................................8 |                                                                                                        |
| 2.2. Quality aspects                                                                                                        | ....................................................................................................8  |
| 2.2.1. Introduction......................................................................................................8  |                                                                                                        |
| 2.2.2. Active Substance...............................................................................................8     |                                                                                                        |
| 2.2.3. Finished Medicinal Product                                                                                           | ..................................................................................9                    |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................11                        |                                                                                                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ......................11                                                                               |
| 2.2.6. Recommendation(s) for future quality development.............................................11                      |                                                                                                        |
| 2.3. Non-clinical aspects                                                                                                   | ............................................................................................12         |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                        |
| 2.3.2. Ecotoxicity/environmental risk assessment                                                                            | .........................................................12                                            |
| 2.3.3. Conclusion on the non-clinical aspects................................................................14             |                                                                                                        |
| 2.4. Clinical aspects                                                                                                       | ..................................................................................................14   |
| 2.4.1. Introduction....................................................................................................14   |                                                                                                        |
| 2.4.2. Pharmacokinetics.............................................................................................15      |                                                                                                        |
| 2.4.3. Pharmacodynamics..........................................................................................21         |                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology...................................................................25             |                                                                                                        |
| 2.4.5. Conclusions on clinical pharmacology.................................................................27              |                                                                                                        |
| 2.5. Clinical efficacy                                                                                                      | ..................................................................................................27   |
| 2.5.1. Main study......................................................................................................27   |                                                                                                        |
| 2.5.2. Discussion on clinical efficacy............................................................................34        |                                                                                                        |
| 2.5.3. Conclusions on the clinical efficacy.....................................................................35          |                                                                                                        |
| 2.6. Clinical safety                                                                                                        | ....................................................................................................35 |
| 2.6.1. Discussion on clinical safety                                                                                        | ..............................................................................40                       |
| 2.6.2. Conclusions on the clinical safety.......................................................................40          |                                                                                                        |
| 2.7. Pharmacovigilance..............................................................................................40      |                                                                                                        |
| 2.8. User consultation                                                                                                      | ...............................................................................................40      |
| 3. Benefit-Risk                                                                                                             | Balance............................................................................41                  |
| 4. Recommendations                                                                                                          | ...............................................................................42                      |
| 5. Appendix                                                                                                                 | .............................................................................................45        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADC

AIDS-defining conditions

AE

Adverse event

AIDS

Acquired immunodeficiency syndrome

ALT

Alanine aminotransferase

ANOVA

Analysis of variance

ANCOVA

Analysis of covariance

AUC0-12hr

Area under the curve from 0 to 12 hours postdose

AUC0-∞

Area under the curve from time zero to infinity

ART

Antiretroviral

AST

Aspartate aminotransferase

ATV

Atazanavir

AUC

Area under the concentration-time curve

BID

Twice daily

BLOQ

Below the assay limit of quantitation

BMI

Body mass index

BUN

Blood urea nitrogen

C12hr

Concentration at 12 hours postdose

Call

Geometric mean concentration of all samples for a single

patient

Cmax

Maximum plasma concentration

CI

Confidence interval

CRO

Clinical research organization

CSR

Clinical study report

CV

Coefficient of variation

DAIDS

Division of AIDs

DMC

Data and Safety Monitoring Committee

EFV

Efavirenz

FCT

Film-coated tablet

FSG

Fasting serum glucose

GCP

Good clinical practice

GM

Geometric mean

GMR

Geometric mean ratio

GSS

Genotypic sensitivity score

HAART

Highly active anti-retroviral therapy

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HR

Heart rate

IC95

Inhibitory concentration - 95%

ICH

International conference on harmonization

IEC

Independent Ethics Committee

IMPAACT

The International Maternal, Pediatric, Adolescent AIDS Clinical

Trials

IRB

Institutional Review Board

LFT

Liver function test

LLOQ

Lower limit of quantification

LPLV

Last patient last visit

LS means

Least-squares means

MED

Minimal effective dose

MRL

Merck Research Laboratories

MSD

Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.

MSE

Mean square error

NIAID

The National Institute of Allergy and Infectious Diseases

NC=F

Non-completer=failure

NNRTI

Non-nucleoside reverse transcriptase inhibitors

NRTI

Nucleoside reverse transcriptase inhibitor

OBT

Optimized Background Therapy

OCSO

Office of Clinical Oversight

OF

Observed failure

OHRP

Office for human research protection

OLPVF

Open-label post-virologic failure

OTC

Over the counter

PI

Protease inhibitor

PID

Patient identification number

PSS

Phenotypic sensitivity score

RBC

Red blood (cell) count

RCC

Regulatory Compliance Center

RNA

Ribonucleic acid

ROC

Receiver operation characteristic

SADR

Suspected adverse drug reaction

SAP

Statistical analysis plan

SD

Standard deviation

SEM

Standard error of the mean

SIP

Study implementation plan

SOP

Standard operating procedure

Tmax

Time to Cmax

TDF

Tenofovir disoproxil fumarate

TDM

Therapeutic Drug Monitoring

TMC-114

Darunavir

TPV

Tipranavir

ULN

Upper limit of normal

VF

Virological failure

WAES

Worldwide adverse experience system

WBC

White blood (cell) count

WPS

Worldwide Product Safety

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd. submitted on 4 July 2011 an extension for a Marketing Authorisation to the European Medicines Agency (EMA) for Isentress 25 mg and 100 mg Chewable tablets, through the centralised procedure falling within Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I (point 2c and d).

The applicant applied for a new pharmaceutical form: chewable tablets associated with the following strength: 25 mg and 100 mg.

In addition, the applicant applied for the following indication: ' in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 2 years.'

Furthermore pursuant to Commission Regulation (EC) No 1234/2008, art.7-2(b), this extension of MA application was grouped with a type II variation to update the section 4.1 of the SmPC for the existing 400mg film-coated tablet with the new paediatric indication (adolescents and children from the age of 6 years) and introduce consequential changes to all sections of the SmPC for the existing 400mg filmcoated tablet (except Sections 1 and 3), Annexes II, IIIa and IIIb.

The application submitted is composed of administrative information, complete quality data and clinical data based on applicant's own tests and studies and/or bibliographic literature.

Merck Sharp &amp; Dohme Ltd. is already the Marketing Authorisation Holder for the Isentress 400 mg Film-coated tablet.

## The legal basis for this application refers to:

Article 19 of Regulation (EC) No 1234/2008 - Extensions of marketing authorizations

The application submitted a grouping as per Article 7 of Regulation (EC) No 1234/2008 including an extension of MA (25 mg and 100 mg Chewable tablets) and a type II variation (new indication in paediatric patients).

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision (P/95/2009) on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP (P/95/2009) was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific Advice

The applicant did not seek scientific advice at the CHMP for the present application.

## Licensing status

Isentress has been given a Marketing Authorisation in the European Union since 20 December 2007.

## 1.2. Manufacturers

## Manufacturer responsible for batch release

Merck Sharp &amp; Dohme B.V. Waarderweg 39 NL-2031 BN Haarlem The Netherlands

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur: Ian Hudson

Co-Rapporteur: Pierre Demolis

- The application was received by the EMA on 4 July 2011.
- The procedure started on 17 August 2011.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 4 November 2011 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 30 November 2011 (Annex 2).
- During the meeting on December 2012, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 December 2012 (Annex 3).
- The applicant submitted the responses to the CHMP consolidated List of Questions on 16 February 2012.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 12 April 2012 (Annex 4).
- During the CHMP meeting on 19 April 2012, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant (Annex 5).
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 18 June 2012.
- The applicant submitted on 13 July 2012 a request to extend the clock stop and delay the oral explanation to September 2012.
- During the CHMP meeting on 19 July 2012, the CHMP agreed on the applicant's proposal to extend the clock stop and delay the oral explanation to September 2012.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 13 September 2012 (Annex 6).
- During the CHMP meeting on 17 September 2012, outstanding issues were addressed by the applicant during an oral explanation before the CHMP.

<div style=\"page-break-after: always\"></div>

- During the CHMP meeting on 20 September 2012, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant (Annex 7).
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 5 October 2012 (Annex 8).
- During the meeting on 18 October 2012, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Isentress on 18 October 2012.
- During the meeting on 13 December 2012, the CHMP issued a revised positive opinion for granting a Marketing Authorisation to Isentress.

## 2. Scientific discussion

## 2.1. Introduction

Isentress (raltegravir) is an integrase strand transfer inhibitor active against the Human Immunodeficiency Virus (HIV-1). Raltegravir inhibits the catalytic activity of integrase, an HIV-encoded enzyme that is required for viral replication. Inhibition of integrase prevents integration of the HIV genome into the host cell genome. HIV genomes that fail to integrate cannot direct the production of new infectious viral particles, so inhibiting integration prevents propagation of the viral infection.

Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on safety and efficacy data from two double-blind, placebo-controlled trials in treatment-experienced patients and one double-blind, active-controlled trial in treatment-naïve patients.

## 2.2. Quality aspects

## 2.2.1. Introduction

Isentress 25 mg chewable tablets are presented as pale yellow round debossed tablets containing 27.16 mg of raltegravir potassium, equivalent to 25 mg raltegravir. Isentress 100 mg chewable tablets are presented as pale orange oval shaped scored and debossed tablets containing 108.6 mg of raltegravir potassium, equivalent to 100 mg raltegravir. The scored 100 mg tablets can be broken in half along the score line to provide a 50 mg dose.

The list of excipients can be found in section 6.1 of the SmPC. The tablets are presented in HDPE bottles with a polypropylene child-resistant screw cap and silica gel desiccant.  Each bottle contains 60 tablets.

## 2.2.2. Active Substance

Raltegravir potassium, the active substance in Isentress 25 mg and 100 mg chewable tablets is identical to the active substance in the authorized Isentress 400 mg film-coated tablets (EU/1/07/436/001-002). Raltegravir is classified as a BCS class II compound, it has a high permeability and low solubility at physiological pH. For information on the active substance reference is made to Module 3.2.S of the marketing authorisation of the 400 mg strength and subsequent quality variations. The active substance specifications are the same as for the 400 mg tablet, with the

<div style=\"page-break-after: always\"></div>

exception of the particle size for which a narrower acceptance limit was set in order to match the particle size of the excipient mannitol.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

The aim was to develop a paediatric formulation for Isentress, suitable for use in children down to two years old, who would not be able to swallow the 400 mg marketed adult tablet. The development focused on finding an effective, palatable dosage form with acceptable size. Clinical needs required the development of two strengths; 25 mg and 100 mg.

In view of the above Quality Target Product Profile (QTPP), the applicant identified the following medicinal product's critical quality attributes (CQA): identity, assay, appearance, elegance, impurities, dissolution, dose uniformity, and deliver suitable stability.

The applicant studied several dosage forms, including orally disintegrating tablets (ODT), chewable tablets and oral granules for suspension. In view of the target population and the bitter taste of the active substance raltegravir, taste masking was identified as an important attribute during the development.

The first step in the development was to develop coated raltegravir granules to achieve taste masking. These taste-masked granules were used as a common starting material for all three formulations. Then, an adequate flavouring system was developed, and the most appropriate dosage form was selected.

Different taste masking systems for paediatric use were evaluated and a granule coating based on Surelease (an ethylcellulose dispersion) and Opadry (a coating suspension) was selected for the final formulation. Ethylcellulose provides taste masking via delayed release due to its insolubility, and when used in the right combination with Opadry, it delays drug release in the oral cavity but still allows immediate release of the drug once in the stomach.

After the development of the taste-masked granules, the applicant focussed on the flavour development and selection of the dosage form. Chewable tablets seemed to be most appropriate based on dissolution data and biocomparability to the initial ODT formulation and the effectiveness of the flavor system based on patient responses to a questionnaire. The chewable tablet formulation required substantial flavor development, because chewing causes some breakage of the taste masking coating, increasing mouth exposure to raltegravir. The flavour development focussed on overcoming the overall basicity of the formulation and included immediate and delayed onset flavouring agents to provide an acceptable flavor. A combination of orange flavor, bitter masking flavor, and banana flavor was chosen for chewable tablets for their particular attributes. The selected flavouring system also includes saccharin and sucralose (two fast onset sweeteners) to provide acceptable sweetness, Magnasweet (a delayed onset sweetener based on monoammonium glycyrrhizinate) to minimize the aftertaste, and mannitol to improve the feel and cooling sensation in the mouth. Questionnaires distributed during clinical trials indicated that the taste acceptability requirements were met. The rationale for the selection of the excipients is adequately explained and justified taking into account the safety profile of these excipients in children. The excipients comply with the Ph.Eur or USP, and the flavouring agents comply with Regulation (EC) No 1334/2008 relating to flavourings for use in foods. No novel excipients are used in the manufacture of Isentress chewable tablets. The full list of excipients can be found in section 6.1 of the SmPC

<div style=\"page-break-after: always\"></div>

The applicant applied a quality by design (QbD) approach during the development of the manufacturing process of the chewable tablets. Design of experiments were performed at development scale to increase process understanding of the granulation and coating step and to define univariate proven acceptable ranges (PAR). A thorough risk analysis was performed for the entire manufacturing process to identify the critical process parameters. The results of the risk analysis were used to define the control strategy to ensure that all CQA and the associated QTPP requirements are achieved and that the manufacturing process is robust and reproducible.

The primary packaging proposed is a HDPE bottle with a polypropylene child-resistant screw cap and silica gel desiccant. Desiccant is included to mitigate risk to product quality from exposure to elevated humidity conditions. The material complies with the relevant European Directives and pharmacopoeial monographs and is adequate to support the stability and use of the medicinal product.

## Adventitious agents

Isentress chewable tablets do not contain materials of animal or human origin. Assurance has been provided that the magnesium stearate and sodium stearyl fumarate are of vegetable origin only.

## Manufacture of the product

The manufacturing process of the chewable tablets consists of a 4-step process and includes delumping and granulation of the drug substance, coating of the drug granules (taste masking), blending and compression. Comprehensive details have been provided on the development and optimisation of the manufacturing process. The process is considered to be a standard manufacturing process.

Critical manufacturing steps have been identified and adequate in-process controls are in place. The test methods and acceptance criteria are considered adequate. Batch analysis data on four 25 mg and four 100 mg batches (pilot scale or larger) show that the chewable tablets can be manufactured reproducible according to the agreed finished product specifications which is suitable for control of this oral dosage form. Formal validation of the manufacturing process in the production facility will take place prior to release of the product to the market. An acceptable validation summary protocol has been provided. This is satisfactory.

## Product specification

The Isentress 25 mg and 100 mg chewable tablets release specifications include tests for appearance, identity (HPLC, FTIR), assay (HPLC), degradation products (HPLC), dissolution, content uniformity, microbiological limits, identity of ferric oxide and tablet breakability (100 mg tablet only). The finished product specifications are standard for immediate release tablets. The proposed test procedures and acceptance criteria comply with the requirements of the Ph.Eur. and ICH guidelines. All tests included in the specification have been satisfactorily described and validated. Appropriate data have been presented to justify the release specifications for each quality characteristic that is controlled. Impurities and degradation products are acceptable from the safety point of view. Batch analysis results comply with the predefined specifications and confirm consistency and uniformity of manufacture and indicate that the process is under control.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability studies on the chewable tablets have been carried out under long term (30°C/75%RH) and accelerated (40°C/75%RH) conditions, on three batches (at least pilot scale), according to the ICH requirements. Up to 52 weeks long term and 26 weeks accelerated stability data have been provided

The batches used for the primary stability studies were prepared in the final market composition and the packaging was representative of the packaging planned for use for the commercial product. Up to 52 weeks additional stability data was provided for bridging batches (at long term and accelerated conditions), manufactured at the commercial site. The parameters tested and analytical methods used in the stability studies are identical to those used for the release specifications, with the exception of identity, content uniformity, microbiological limits and identity of ferric oxide which are tested at release only, and hardness which is tested at the end of shelf-life. The analytical methods used were stability indicating. No significant changes were observed at any storage condition.

In-use stability studies were performed to evaluate the risk of tablet discoloration during the in-use period (i.e. after the induction seal has been breached). Based on the results no in use shelf-life is considered necessary. The applicant confirmed that the in-use stability study will be repeated at the end of the expiry period for the chewable tablets. This is acceptable on the basis of the in-use stability results obtained so far.

In addition, two batches were exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. The results demonstrated that the raltegravir chewable tablets can be considered to be stable when exposed to light. Based on the available stability data, the proposed shelf-life and storage conditions as stated in the SmPC are acceptable.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Isentress 25 mg and 100 mg chewable tablets are paediatric strengths. The chewable tablets are manufactured using the same active substance as the authorised 400 mg tablets. Different excipients are used however, to make the tablets chewable and palatable. All excipients were found acceptable for use in the paediatric population.

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have satisfactory and uniform performance in the clinic.

At the time of the CHMP opinion, there were no unresolved quality issues.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on TSE safety.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Since RAL is already approved by oral route, as film-coated tablets, no additional non-clinical studies have been performed to support this application. The MAH has previously submitted juvenile toxicity studies in the rat and no additional toxicities were observed in juvenile animals. The CHMP considers this approach acceptable.

## 2.3.2. Ecotoxicity/environmental risk assessment

A summary of the Environmental Risk Assessment is presented in Table 1.

Table 1. Table 2  ERA Summary

| Substance (INN/Invented Name): raltegravir Isentress             | Substance (INN/Invented Name): raltegravir Isentress   | Substance (INN/Invented Name): raltegravir Isentress                                                                              | Substance (INN/Invented Name): raltegravir Isentress                                                                                                                                       |
|------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PBT screening                                                    |                                                        | Result                                                                                                                            | Conclusion                                                                                                                                                                                 |
| Bioaccumulation potential log D ow DT 50                         |                                                        | 0.45 at pH 7.4 DT 50,sediment = 182 days (Choptank anaerobic system)                                                              | Potential PBT: no DT 50sediment >180 therefore classified as persistent                                                                                                                    |
| Phase I                                                          |                                                        |                                                                                                                                   |                                                                                                                                                                                            |
| Calculation                                                      | Value                                                  | Unit                                                                                                                              | Conclusion                                                                                                                                                                                 |
| PEC surfacewater                                                 | 8.0                                                    | µ g/L                                                                                                                             | > 0.01 threshold                                                                                                                                                                           |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate         | Phase II Physical-chemical properties and fate                                                                                    | Phase II Physical-chemical properties and fate                                                                                                                                             |
| Study type                                                       | Protocol                                               | Results                                                                                                                           | Remarks                                                                                                                                                                                    |
| Adsorption-Desorption                                            | OECD 121                                               | log K oc = 1.64                                                                                                                   | <4 threshold                                                                                                                                                                               |
| Inherent Biodegradability                                        | OECD 302B                                              | DT 50 = 224 hours                                                                                                                 | Not readily biodegradable                                                                                                                                                                  |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                               | DT 50, water aerobic = 6.4-6.5 days DT 50, water anaerobic = 5.2-6.8 days DT 50, sediment = 90-182 days DT 50, whole system = not | Relative %of parent and metabolites in the non-extractable component(s) bound to sediment not discernible > 10% of radioactivity present in the sediment at termination of study (Day 100) |

Isentress Assessment report

<div style=\"page-break-after: always\"></div>

| Substance (INN/Invented Name):                | Substance (INN/Invented Name):                                                                     | raltegravir Isentress                                                                              | raltegravir Isentress                                                                              | raltegravir Isentress       | raltegravir Isentress       | raltegravir Isentress                                                  | raltegravir Isentress                                                  |
|-----------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Phase IIa Effect studies                      | Phase IIa Effect studies                                                                           | Phase IIa Effect studies                                                                           | Phase IIa Effect studies                                                                           | Phase IIa Effect studies    | Phase IIa Effect studies    | Phase IIa Effect studies                                               | Phase IIa Effect studies                                               |
| Study type                                    | Study type                                                                                         | Protocol                                                                                           | Endpoint                                                                                           | Endpoint                    | value Unit                  | value Unit                                                             | Remarks                                                                |
| Algae, Growth Inhibition test on              | Algae, Growth Inhibition test on                                                                   | OECD 201                                                                                           | NOEC                                                                                               | NOEC                        | 1600 µg/L                   | 1600 µg/L                                                              | Pseudokirchnieriella subcapitata 96-hr exposure                        |
| Daphnia sp. Reproduction Test                 | Daphnia sp. Reproduction Test                                                                      | OECD 211                                                                                           | NOEC                                                                                               | NOEC                        | 9500 µg/L                   | 9500 µg/L                                                              | 21-day study                                                           |
| Fish, Early Life Stage Toxicity Test          | Fish, Early Life Stage Toxicity Test                                                               | OECD 210                                                                                           | NOEC                                                                                               | NOEC                        | 9300 µg/L                   | 9300 µg/L                                                              | Pimephales promelas 33-day study                                       |
| Activated Sludge, Respiration Inhibition Test | Activated Sludge, Respiration Inhibition Test                                                      | OECD 209                                                                                           | EC50                                                                                               | EC50                        | 10 6 µg/L                   | 10 6 µg/L                                                              | 3-hour exposure                                                        |
| Phase IIb Studies                             | Phase IIb Studies                                                                                  | Phase IIb Studies                                                                                  | Phase IIb Studies                                                                                  | Phase IIb Studies           | Phase IIb Studies           | Phase IIb Studies                                                      | Phase IIb Studies                                                      |
| Study type                                    | Study type                                                                                         | Protocol                                                                                           | Endpoint                                                                                           | Endpoint                    | value Unit                  | value Unit                                                             | Remarks                                                                |
| Sediment dwelling organism                    | Sediment dwelling organism                                                                         | OECD 218                                                                                           | NOEC                                                                                               | NOEC                        | 100 mg/kg                   | 100 mg/kg                                                              | Chironomus riparius 28-day study                                       |
| Outcome of phase II studies                   | Outcome of phase II studies                                                                        | Outcome of phase II studies                                                                        | Outcome of phase II studies                                                                        | Outcome of phase II studies | Outcome of phase II studies | Outcome of phase II studies                                            | Outcome of phase II studies                                            |
|                                               | PNEC                                                                                               | PNEC                                                                                               | PNEC                                                                                               | PEC                         | PEC                         | PEC/PNEC, and conclusion                                               | PEC/PNEC, and conclusion                                               |
| Surface water                                 | 160 µg/L based on: NOEC determined in the most sensitive aquatic species = 1600 µg/L (algae study) | 160 µg/L based on: NOEC determined in the most sensitive aquatic species = 1600 µg/L (algae study) | 160 µg/L based on: NOEC determined in the most sensitive aquatic species = 1600 µg/L (algae study) | 8 µg/L                      | 8 µg/L                      | 0.05 (< 1) Raltegravir does not pose a risk to the aquatic environment | 0.05 (< 1) Raltegravir does not pose a risk to the aquatic environment |
| Ground water                                  | 950 µg/L based on: NOEC determined in the 21-day daphnia study = 9500 µg/L                         | 950 µg/L based on: NOEC determined in the 21-day daphnia study = 9500 µg/L                         | 950 µg/L based on: NOEC determined in the 21-day daphnia study = 9500 µg/L                         | 2 µg/L (0.25xPEC SW )       | 2 µg/L (0.25xPEC SW )       | 0.002 (<1) Raltegravir does not pose a risk to ground water organisms  | 0.002 (<1) Raltegravir does not pose a risk to ground water organisms  |
| Micro- organisms                              | 10 5 µg/L based on: NOEC determined in the ASRIT = 10 6 µg/L                                       | 10 5 µg/L based on: NOEC determined in the ASRIT = 10 6 µg/L                                       | 10 5 µg/L based on: NOEC determined in the ASRIT = 10 6 µg/L                                       | 8 µg/L (PEC SW )            | 8 µg/L (PEC SW )            | 8.10 -5 (<0.1) Raltegravir does not pose a risk to micro-organisms     | 8.10 -5 (<0.1) Raltegravir does not pose a risk to micro-organisms     |

The information regarding the ERA suggests that RAL and/or its metabolites will not constitute a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Conclusion on the non-clinical aspects

No new non-clinical studies have been performed in support of this application and no further studies are considered necessary by the CHMP.  The available pharmacokinetic and toxicology data are considered sufficient by the CHMP to support the use of RAL in paediatric patients from 2 to 18 years of age.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Protocol                  | Dose(s) of Raltegravir Studied                                                                                                                                                                   | Final Dose Selected                                                                                                                                                                | Number Receivin g Raltegra vir   | Population                                | Key Purpose                                                                                           |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Protocol 068              | A: 400 mg raltegravir FMI poloxamer tablet B: 400 mg (4 x 100 mg) raltegravir CT C: 400 mg raltegravir oral granules in a liquid suspension D: 400 mg (4 x 100 mg) raltegravir CT after high fat | N/A                                                                                                                                                                                | 12                               | Healthy adult volunteers                  | PK and Safety                                                                                         |
| IMPAACT (P1066) Study 022 | meal Adult Tablet: Dose Ranging: Weight based to approximately 6 mg/kg BID; 200 - 600 mg BID. Chewable Tablet: Dose Ranging: Weight based to approximately 8 mg/kg BID; 75 - 300 mg BID.         | Adult Tablet: 400 mg BID for patients 12-18 years and 6-11 years and ≥ 25 kg. Chewable Tablet: Weight based to approximately 6 mg/kg BID (max 300 mg BID) for patients 2-11 years. | 87 39                            | Treatment- experienced pediatric patients | Demonstration of PK and short term safety for dose finding; safety and efficacy with long term dosing |

<div style=\"page-break-after: always\"></div>

| Protocol   | Dose(s) of Raltegravir Studied                                                                     | Final Dose Selected   |   Number Receivin g Raltegra vir | Population             | Key Purpose                                                                                                                                                                                                                                       |
|------------|----------------------------------------------------------------------------------------------------|-----------------------|----------------------------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 071  | RAL: 800 mg q.d. RAL: 400 mg b.i.d. and 800 mg q.d. All patients took one tablet of TRUVADA™ daily | N/A                   |                              775 | Treatment naïve adults | Evaluate the long-term safety, tolerability, and efficacy of oncedaily (q.d) RAL 800 mg PO compared with twice daily (b.i.d.) RAL 400 mg PO when each was given in combination with TRUVADA™ for up to 96 weeks, which was extended to 120 weeks. |

## 2.4.2. Pharmacokinetics

## Analytical Methods

The analytical method for the determination of RAL in human plasma used HPLC-MS/MS. The two validated procedures that were used had linear calibration ranges of 1 - 3000 ng/mL and 10 - 10,000 ng/mL. Separate bio analytical reports have been provided.

## Study 068

Study 068 was an open label cross over study to compare the adult tablet as marketed with the candidate chewable tablet. It also evaluated the effect of food on absorption after dosing with the chewable tablet. Subjects each received 4 single dose (400 mg) treatments in a randomised order and with at least 4 days of washout between each treatment period. PK samples were obtained over 72h after each dosing.

- Treatments A and B were administered in the fasting state.
- Treatment D was administered after a high fat breakfast of 827 kcal and 57% fat content.

The data from treatment C wasn't following into the scope of the present application since a different formulation was used.

The comparison between the chewable tablet (treatment B) and adult tablet (FMI poloxamer formulation; treatment A) when administered in the fasting state gave a GMR for AUC0-∞ at 1.78 and 90% CI 1.47, 2.15. The Geometric Mean Ratio (GMR) for Cmax was 3.22, with 90% CI 2.37, 4.38. Thus, AUC0-∞ and Cmax observed with the chewable tablet were higher than obtained with the marketed adult tablet and the two formulations were not bioequivalent. Peak concentrations also occurred earlier such that median Tmax was only 0.5 h for the chewable tablet vs. 4 h for the adult tablet. The C12h concentrations and half-lives were comparable between formulations.

The administration of the chewable tablet with a high-fat meal (treatment D) slowed the rate of absorption with no statistically meaningful change in the extent of absorption but C12h was improved.

## Study 022 (P1066; IMPAACT)

Study 022 (P1066; IMPAACT) is an on-going Phase I/II, multi-center, open-label, non-comparative study of approximately 140 HIV-1 infected children and adolescents 4 weeks through 18 years of age

<div style=\"page-break-after: always\"></div>

to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen.

The data discussed as part of the present application are related to raltegravir administered orally as the adult tablet or as a chewable tablet (2 through 18 years of age).  A third formulation, oral granules for suspension in water, was available to permit study of patients 4 weeks through 2 years of age. These data are not part of the present submission.

## Formulations

- Adult tablets (100, 200 and 400 mg erodible tablet formulation; note that only the 400 mg tablet is approved),
- Chewable tablets (25, 50 and 100 mg unscored); the 50 mg has been dropped.

Note: The 50 mg dose was dropped during the study since this strength was not required to titrate the patients. However, the data related to the 50 mg dose were submitted by the applicant in the clinical study report for study P022 which was part of the initial submission.

The 100 mg chewable tablet used in study 068 was of the same formulation and composition as that used in study 022.

Note that the commercial tablet is scored and the applicant performed multimedia (pH 1.2, 4.5, and 6.8) comparative dissolution profiles using the same dissolution testing conditions to bridge between the tablets used in the trial and the commercial ones.

Data from a study on tablets split by hand that quantitate the equivalence of the resulting halves and the amount of powder mass lost during the splitting operation were provided. Comparative dissolution data were obtained for 100 mg scored tablet halves vs. the intact tablet. Hence, the 100 mg chewable tablet can be divided into equal 50 mg doses; however, as indicated in the SmPC, it is not recommended to break the tablets since it is possible to build the dosage with whole 25mg and 100mg chewable tablets.

Since the tablets and the chewable tablets are not bioequivalent, the following statement has been included on the outer carton and on the bottle label the statement \" Do not switch between the chewable tablets and the 400 mg tablet, without first talking with your doctor .\"

## Objectives

The study design is further described in the section 2.5. The clinical pharmacology objectives were:

- To evaluate the steady state plasma concentration profiles and PK parameters of raltegravir in children and adolescents.
- To evaluate the steady state plasma concentration profiles and PK parameters of raltegravir administered as a poloxamer tablet, a chewable tablet or oral granules for suspension.
- To collect sparse concentration-time data to create a population PK model to describe paediatric exposure to raltegravir and to assess drug-drug interactions.

The aim was to determine a formulation-specific paediatric dose that would provide approximately the same plasma exposure to that achieved in adults using 400 mg BID delivered with the marketed tablet. On this basis the target minimum exposure for each cohort was a GM AUC0-12h between 14 and 25 μM·hr with a concurrent GM C12h exceeding 33 nM (i.e. the IC95). Additionally, for safety considerations, the maximum AUC0-12h was to be &lt; 45 μM·hr, which represents half the AUC0-24h that was observed when 1600 mg was administered in Phase I studies.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 1. Study design P1066 (DLP 14/02/2012)

<!-- image -->

Note: The week 48 data for Cohort III was submitted with the responses to the D120 LoQ (DLP 15/07/2012)

Stage I examined PK, short-term tolerability and safety in a limited number of patients to permit dose selection for further study in Stage II. Stage I commenced with dosing Cohort I and progressed sequentially to the younger cohorts, in each case obtaining preliminary data from a mini-cohort. The background ARV was optimised after sampling for PK evaluation.

Stage II involved raltegravir dosing for 48 weeks with an optimised background ARV regimen. Sparse PK sampling was performed during the chronic dosing stage.

Upon completion of 48 weeks study treatment raltegravir was made available to patients via a protocol extension inclusive of 5 years from initial exposure.

Cohorts I (≥  12 to 18 years - adult tablets) and Cohort IIA (≥  6 to &lt; 12 years - adult tablets) received poloxamer film-coated tablets twice daily (same formulation as the approved 400 mg tablet). Three strengths (100, 200, and 400 mg) were provided for dosing flexibility.

Cohorts IIB (≥  6 to &lt; 12 years - chewable tablets) and III (≥  2 to &lt; 6 years - chewable tablets) received chewable tablets twice daily. Three strengths (25, 50, and 100 mg) were initially provided to allow dosing flexibility in 25 mg intervals but the 50 mg dose strength was later removed.

## Intensive PK sampling

It was performed for all patients in Stage I of each cohort and also following an initial dose or dose change of raltegravir. Intensive PK sampling occurred between Days 5 and 12 after the first raltegravir dose and between Days 7 and 14 after dose adjustment. There was witnessed dosing at approximately 12 hours after the previous dose. Samples were collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post dose. The large majority of patients had plasma concentrations at all time points well above the LLOQ.

Of note, patients were fasted only on the day of PK collection during the intensive PK sampling phase; on all other study days, administration of raltegravir was allowed irrespective of food intake.

## Population PK sampling

It was performed for all patients in Stages I and II at Weeks 4, 8, 12 and 24. One blood sample was collected between 10 and 14 hours post dose at Weeks 4 and 12; two blood samples separated by 2

<div style=\"page-break-after: always\"></div>

hours were collected between 0.5 and 6 hours post dose at Week 8; and two samples separated by 2 hours were collected between 6 and 12 hours post dose at Week 24.

## Dose-finding

## Dose-finding with adult tablet formulation (using 100, 200 and 400 mg tablet sizes)

The figure below shows the progression of studied doses and resulting PK parameter values for Cohorts I (≥ 12 to 18 years) and IIA (≥ 6 to &lt; 12 years) using the adult tablet formulation.

Figure 2. Schematic of studied and associated PK parameter values for cohort I and IIA (adult tablets)

<!-- image -->

The first four patients in Cohort I (≥  12 to &lt; 19 years), Stage 1 received ~6 mg/kg BID (maximum dose 800 mg) using the adult tablet and under non-fasted conditions. The full Cohort I did not meet the AUC PK targets. Since food may have contributed to a lower observed AUC, intensive PK sampling under fasting conditions led to dose adjustment to ~8 mg/kg BID (maximum dose of 600 mg). Subsequently, 11 new patients were enrolled in Cohort I for intensive PK evaluations after dosing in the fasting state. The dose adjustment to 8 mg/kg twice daily meant that the majority of the patients actually received 400 mg twice daily giving a range of 6.7 to 10.5 mg/kg. Data obtained showed that on dosing with ~8mg/kg the GM AUC0-12hr (15.7 μM·hr) and C12h values (333 nM) for this cohort fell within the pre-defined targets. It was concluded that 400 mg BID would provide mean PK parameter values within the target range.

For Cohort IIA (≥ 6 to &lt; 12 years), dosing was initiated in four patients at 8 mg/kg BID using adult tablet formulations under non-fasted conditions and then 10 new patients were enrolled to receive ~8 mg/kg BID (maximum dose 600 mg) using adult tablet formulations under fasted conditions. The initial dose of approximately 8 mg/kg twice daily gave a GM AUC0-12hr (12.0 μM·hr) below the minimum target of 14 μM·hr. A fixed dose of 400 mg BID for all patients was then administered and resulted in GM AUC0-12hr (15.8 μM·hr) and C12hr values (246 nM) that met the pre-defined targets.

<div style=\"page-break-after: always\"></div>

Two subjects with weights below 25 kg had extremely high AUC0-12hr values when administered 400 mg BID while a third subject had AUC0-12hr below the target value. On the contrary, the AUC0-12hr values in children aged 6 with body weight ≥ 25 kg were nearly identical to those observed in adults.

Based on these findings, it is recommended to use a fixed dose of the adult formulation 400 BID when body weight is ≥ 25 kg in children aged 6 to 18 years.

## Dose-finding with chewable tablets (using 25, 50 and 100 mg tablet sizes)

The next figure shows the progression of studied doses and resulting PK parameter values for Cohorts IIB (≥ 6 to &lt; 12 years) and III (≥ 2 to &lt; 6 years) when dosed with the chewable tablet.

Figure 3. Schematic of studied and associated PK parameter values for cohort IIB and III (chewable tablets)

Note - The tables mentioned in the figure were included in the marketing authorisation application

<!-- image -->

The first 4 subjects enrolled in Cohort IIB received approximately 8 mg/kg twice daily, which resulted in a GM AUC0-12hr that was greater than the pre-defined range of 25 μM·hr. Therefore the dose was reduced to approximately 6 mg/kg up to a maximum dose of 300 mg twice daily. Six additional subjects were enrolled at the revised dose and the original subjects had their dose changed. The resulting geometric mean AUC0-12hr and C12hr were within the target ranges. Hence, a dose of approximately 6 mg/kg (maximum 300 mg) twice daily of the chewable tablet was chosen for continued study in the age group 6-11 years.

Twelve patients were enrolled in Stage 1 of Cohort III. Using the recommended 6mg/kg dosing the GM AUC0-12hr and C12hr were within the target ranges.

<div style=\"page-break-after: always\"></div>

Weight-based dosing of the chewable tablet for children ages 6 to less than 12 years old with body weight &lt; 25 kg was considered to be supported by examination of clearance as a function of weight. Indeed, clearance values appear relatively constant in children with body weight ≥25 kg, and begin to trend downward with decreasing weights below 25 kg, suggesting that weight-based dosing would be more appropriate for those &lt; 25 kg to maintain similar exposures to those seen in adults.

Since the minimum weight reported in this study was 11.8 kg and there were only seven children in Stage I with weights between 11.8 and 14 kg, the chewable tablets should be used from 12 kg upwards.

Based on these findings, it is recommended to use the weight based regimen of 6mg/kg, to maximum dose 300 mg, twice daily, of the chewable tablets when body weight is ≥ 12 kg in children aged 2 to 12 years.

## Analyses

Both intensive and sparse PK data were collected in this study. Since intensive PK data were collected under the most controlled conditions and with observed dosing, intensive PK assessments provide most accurate estimate of PK parameters associated with the administered dose. Hence, the data from the intensive PK data were considered more closely during the application.

## Analyses based on sparse sampling data

For all Cohorts, the three non-model based exposure summary measures that were calculated based on the observed sparse concentration data were:

- Call = GM of all samples for a particular patient, regardless of time of collection
- GM C12h = GM of all samples for a particular patient collected between 10-14 h post-dose
- Cmin = minimum value of all samples for a particular patient, regardless of time of collection

Concentrations that were &lt; LLOQ (10 ng/mL) were assigned a value of ½*LLOQ = 5 ng/mL = 11 nM. Values of the non-model based parameters for the Final Dose population from sparse concentration data are shown in the table 2.

Table 2. Geometric Mean (%CV) values for Non-Model based RAL PK parameters calculated from sparse concentration data (cohorts I, IIA, IIB, III, final dose population)

| Cohort   |   N | Call (nM)   |   N | GM C12hr (nM)   |   N | Cmin (nM)   |
|----------|-----|-------------|-----|-----------------|-----|-------------|
| I        |  58 | 354 (112)   |  53 | 225 (175)       |  58 | 72 (163)    |
| ILA      |   4 | 1227 (80)   |   2 | 558 (93)        |   4 | 262 (51)    |
| IIB      |  13 | 355 (82)    |  12 | 108 (101)       |  13 | 50 (77)     |
| III      |  20 | 267 (164)   |  19 | 130 (161)       |  20 | 57 (170)    |

There was less variability in PK observed when dosing with chewable tablets versus the adult tablet based on all the intensive sampling data obtained in the fasting state. On this basis, no modelling was conducted using the data from Cohorts I and IIA in which the adult tablet was used. A model was developed using the data from Cohorts IIB and III in which the chewable tablet was used to estimate values of AUC0-12hr, Cmax and C12hr based on the sparse concentration data. Values of the modelbased parameters for the Final Dose population on the sparse concentration data are shown in the table 3.

<div style=\"page-break-after: always\"></div>

Table 3. Geometric Mean (%CV) values for Model based RAL PK parameters calculated from sparse concentration data (cohorts IIB, III, final dose population)

| Cohort   |   N | AUCo-12hr (uM*hr)   | (uM)      | C12hr (nM)   |
|----------|-----|---------------------|-----------|--------------|
| IIB      |  13 | 25.3 (23)           | 10.8 (31) | 244 (89)     |
| III      |  20 | 19.7 (75)           | 8.7 (26)  | 157 (176)    |

## Analyses based on intensive PK data

Overall exposure (GM AUC0-12hr) and GM Ctrough levels from the intensive PK analyses, both the filmcoated and chewable tablets in Cohorts I to III, are presented in table 4.

Table 4. Raltegravir Pharmacokinetic Parameters IMPAACT P1066

| Age                 | Formulation     | Dose                                       |   N † | Geometric Mean (%CV) AUC 0-12hr (μM*hr)   | Geometric Mean (%CV) C 12hr (nM)   |
|---------------------|-----------------|--------------------------------------------|-------|-------------------------------------------|------------------------------------|
| 12 through 18 years | 400 mg tablet   | 400 mg twice daily, regardless of weight ‡ |    11 | 15.7 ( 98% )                              | 333 ( 78% )                        |
| 6 through 11 years  | 400 mg tablet   | 400 mg twice daily, for patients ≥25 kg    |    11 | 15.8 ( 120% )                             | 246 ( 221% )                       |
| 6 through 11 years  | Chewable tablet | Weight based dosing, see Table 1           |    10 | 22.6 ( 34% )                              | 130 ( 88% )                        |
| 2 through 5 years   | Chewable tablet | Weight based dosing, see Table 1           |    12 | 18.0 ( 59% )                              | 71 ( 55% )                         |

Number of patients with intensive pharmacokinetic (PK) results at the final recommended dose. ‡ Patients in this age group received approximately 8 mg/kg dose at time of intensive PK which met PK and safety targets. Based on review of the individual profiles and receipt of a mean dose of 390 mg, 400 mg twice daily was selected as the recommended dose for this age group.

†

## Chewable tablet doses

There was no obvious trend in Cohorts IIB and III for the PK parameters values to vary by dose or tablet potency received (i.e. 25mg, 100mg).

## 2.4.3. Pharmacodynamics

## Study 071

Study 071 was a phase III multicenter, double-blind, randomized, active comparator-controlled clinical trial to study the safety and efficacy of once daily raltegravir versus twice daily raltegravir, each in combination with Truvada (emtricitabine/tenofovir disoproxil fumarate), in treatment-naïve HIV infected patients. Study 071 showed a statistically significant difference between 400 mg BID and 800 mg QD regimens in the pre-defined primary analysis at Week 48.

Isentress Assessment report

<div style=\"page-break-after: always\"></div>

Data comparing regimens containing raltegravir 400 mg BID vs. 800 mg QD in this study have suggested a PK/PD relationship with Ctrough, where low Ctrough in the 800 mg QD arm was associated with a higher probability of virologic failure. Indeed, a receiver operating characteristic (ROC) analysis identified this threshold Ctrough of 45 nM. This was consistent with the results of a quartile analysis, showing a lower efficacy response in patients in the lowest quartile of Ctrough values in the 800 mg QD arm of the study, where the upper bound of the lowest quartile was a Ctrough value of 43 nM.

The failure to demonstrate non-inferiority for 800 mg QD vs. 400 mg BID and the differences in PK, especially with respect to Ctrough, were informative to the CHMP with regard to RAL PK/PD relationship and the relative importance of C12h (effectively Ctrough) versus AUC. Though it is not been possible to identify a robust threshold for Ctrough, the available data suggest a threshold value ~ 45 nM. Hence, though it was not part of the original PK target definition for study 022, this information has been taken into account in the present assessment.

## Study 022

## Analyses based on sparse sampling data

The following assumptions were made for the PK/PD analysis: dosing history and sampling times were collected appropriately, plasma concentrations are at steady state for all visits where PK was collected such that longitudinal variation in PK does not need to be considered (except for the time points where there is a change in dose), samples drawn at different visits can thus be pooled together.

Exploratory plots of PK/PD associations were made between the various PK parameters and each of the efficacy parameters. To assess the effect of PK parameter (GM C12hr or GM Call) on the two efficacy endpoints a logistic regression model with PK parameter and baseline HIV RNA level as predictors was used. These two factors were assumed to have no interaction.

Based on all patients in the Final Dose population there were statistically significant associations detected for all combinations of sparse PK parameters and efficacy measures in the analyses of data from all four Cohorts and from Cohorts I and IIA (adult tablet) but not for Cohorts IIB and III (chewable tablet). When those with ≥ 2 BLOQ PK values were removed from the analysis, statistically significant relationships were detected only between GM C12h and HIV RNA &lt;50 copies/mL for all four cohorts. Of note, a statistically significant relationship between GM C12h and HIV RNA &lt;50 at Week 48 of treatment was also observed in treatment-experienced adults in studies 018 and 019 (submitted as part of the initial marketing authorisation application) but consistent relationships between GM C12h and other efficacy endpoints (e.g. HIV RNA &lt; 400, virological failure and presence of resistance mutations) were not observed.

These data should be interpreted with caution due to the relatively small number of patients, the large inter- and intra-subject variability in raltegravir PK and the small number of samples that went into the calculation of GM C12h for each patient (median = 2). In addition, the BLOQ values potentially represent lack of adherence to the treatment regimen. In this regard, the pill count data are difficult to interpret given the large amount of missing data.

The virological response rates were highest in patients with no or only one value BLOQ and these patients mostly had GM Call values above 100 nM. In addition, for all Cohorts pooled in the Final Dose population, 64.2% with no BLOQ values achieved HIV RNA &lt;50 copies/mL at Week 24 compared to 35.7% with 1 BLOQ value and 23.1% with multiple BLOQ values.

The sparse PK data collected in pediatric patients, and using the threshold value of ~ 45 nM, the distribution of individual Ctrough values obtained using the chewable tablet formulation are shown in Figure 4. These data confirm that the yield Ctrough &gt;45 nM in the large majority of patients. The

Isentress Assessment report

<div style=\"page-break-after: always\"></div>

percentage of patients with Ctrough &lt; 45 nM is ~11% in the youngest age group (2 to less than 6 years of age), which is reasonably consistent with results from the intensive PK analysis, and smaller than that observed with 800 mg QD in adults (27%). The analysis shown treats values BLOQ as missing, which assumes these values are due to non-compliance (which no amount of dose adjustment will address) rather than suboptimal dosing.

Figure 4. Ctrough values from Sparse PK in Pediatrics (Study 022) versus in Adults Taking 400 mg BID or 800 mg QD (QDMRK, Study 071)

<!-- image -->

## Analyses based on intensive PK data

The intensive PK data collected in pediatric patients, and using the threshold value of ~ 45 nM, the distribution of individual Ctrough values obtained using the chewable tablet formulation are shown in Figure 5. For the chewable tablet, none of the ten patients in Cohort IIB (6 to less than 12 years old) had Ctrough less than 45 nM, and, for Cohort III (2 to less than 6 year olds), there were 1 or 2 patients out of 12 with Ctrough &lt;45 nM. Note that one of these two values, the very low trough value, is not a measured value - due to administration of a dose in this patient between 8 and 12 hours postdose that invalidated the nominal C12hr sample collected, the value shown was extrapolated using a very conservative method and is very likely an underestimate. The observed distribution of Ctrough for children receiving the chewable tablet is above that observed for adults receiving 800 mg QD of raltegravir in study 077, where 12 of 22 patients (54%) had Ctrough values below 45 nM.

<div style=\"page-break-after: always\"></div>

Figure 5. Ctrough values from Intensive PK in Pediatrics (Study 022) versus in Adults Taking 400 mg BID or 800 mg QD (QDMRK, Study 071)

<!-- image -->

Based on intensive sampling and the final dose cohort the comparisons of GM AUC0-12 and Ctrough, including numbers with Ctrough &lt;45nM and AUC &lt; 14-25nM.h, were as follows:

Table 5. GM AUC 0-12 and Ctrough, including numbers with Ctrough &lt;45nM

| Cohort (n*)                  | GM AUC (CV)       | GM Ctrough (CV)   | #patients with Ctrough <45nM (n/N)   | #patients with AUC <14-25 nM.h   |
|------------------------------|-------------------|-------------------|--------------------------------------|----------------------------------|
| Adult 400mg BID (n=20)       | 13.4-14.3 (56-60) | 257 (167)         | 1/20                                 |                                  |
| Adult 800mg QD (n=22)        | 30.87 (70)        | 40 (111)          | 12/22                                |                                  |
| Cohort I 400mg BID (n=11)    | 15.7 (71)         | 333 (78)          | 0/11                                 | 5/11                             |
| Cohort IIa 400mg BID (n=11)  | 15.8 (128)        | 246 (221)         | 1/11                                 | 5/11                             |
| Cohort IIb 6mg/kg BID (n=10) | 22.6 (34)         | 130 (88)          | 0/10                                 | 1/10                             |
| Cohort III 6mg/kg BID (n=12) | 18.0 (59)         | 71 (55)           | 2/12                                 | 5/11                             |

*Number of patients with intensive PK results at the final recommended dose

<div style=\"page-break-after: always\"></div>

Both the film-coated and chewable tablets in Cohorts I to III met the pre-specified PK targets. The GM Ctrough decreased with decreasing age, while there was no consistent trend for the GM AUC. The number and proportion with AUC &lt; 14 nM was not higher in the cohorts that received 6 mg/kg using chewable tablets vs. the Cohorts that received adult tablets. With the exception of 800 mg once daily, which is not an approved regimen, the individual numbers with Ctrough &lt; 45 nM were 0-2 per group.

## 2.4.4. Discussion on clinical pharmacology

## Design and conduct of clinical studies

Study 071 was a phase III multicenter, double-blind, randomized, active comparator-controlled clinical trial to study the safety and efficacy of once daily raltegravir versus twice daily raltegravir, each in combination with Truvada (emtricitabine/tenofovir disoproxil fumarate), in treatment-naïve HIV infected patients. Study 071 showed a statistically significant difference between 400 mg BID and 800 mg QD regimens in the pre-defined primary analysis at Week 48. The failure to demonstrate noninferiority for 800 mg QD vs. 400 mg BID and the differences in PK, especially with respect to Ctrough, were informative to the CHMP with regard to RAL PK/PD relationship and the relative importance of C12h (effectively Ctrough) versus AUC.

Study 022 is an ongoing Phase I/II, multi-center, open-label, non-comparative study in HIV-1 infected children and adolescents ages ≥4 weeks to &lt;19 years of age to evaluate the safety, tolerability, pharmacokinetic parameters and efficacy of raltegravir.

Patients were stratified by age, enrolling adolescents first (Cohort I) and then successively younger children. Patients received either the 400 mg film-coated tablet formulation (Cohorts I and IIA; 6 through 18 years of age) or the chewable tablet formulation (Cohorts IIB and III; 2 through 11 years of age). Raltegravir was administered with an optimized background regimen.

Study 022 design includes two stages. The initial dose-finding stage (Stage I) included intensive pharmacokinetic evaluation. Dose selection for each cohort was based upon achieving similar raltegravir plasma exposure as seen in adults, and adequate trough concentrations based on the in vitro IC95 for antiviral activity. Specifically, the goal was to maintain both a GM AUC0-12hr between 14 and 25 uM*hr and a GM C12hr greater than 33 nM (the in vitro IC95), as well as to demonstrate acceptable short term safety. After dose selection, additional patients were enrolled (Stage II) for evaluation of long term safety, tolerability, and efficacy. Sparse PK sampling was performed during the chronic dosing stage. Of the 126 patients enrolled (All Treated population) in Cohorts I to III, 96 patients received only the recommended dose of raltegravir, and are considered the Final Dose population.

## Data and additional analyses

Study 022 aimed to identify regimens providing comparable plasma exposure to that achieved in adults when dosed at 400 mg BID using the marketed tablets. In principle, this is an appropriate and sufficient approach for selecting a paediatric dose schema when the PK/PD is expected to be the same in children as in adults. The target GM AUC0-12h was based on data obtained from HIV-1 infected adults during 400 mg BID monotherapy and on dosing along with tenofovir and lamivudine while the target C12h corresponded to the in-vitro IC95 for antiviral activity. Since two formulations were proposed for use and since the two were shown not to be bioequivalent, separate dose recommendations were identified, with an option to use either formulation in the age group 6-11 years.

The objective of Study 022 dose finding was to match overall exposure (AUC) observed with 400 mg BID regimen in adults (geometric mean (GM) value 14 - 25 μM·hr), and maintain reasonable GM Ctrough

Isentress Assessment report

<div style=\"page-break-after: always\"></div>

levels, in this case defined as above the IC95 of 33 nM. Both the film-coated and chewable tablets in Cohorts I to III met the pre-specified PK targets.

CV% was lower with the chewable tablets versus adult poloxamer tablets. Across the study Cohorts it is also clear that CV% is not higher when using chewable tablets in IIB and III as compared to adults and to Cohorts I and IIA, which were dosed with 400 mg BID.

The CHMP considered that the data from study 071 were informative with regard to the PK/PD relationship and the relative importance of C12h (effectively Ctrough) vs. AUC. Indeed, the failure to demonstrate non-inferiority for 800 mg QD vs. 400 mg BID could be attributable to the low Ctrough values. It has not been possible to identify a robust threshold but the available data suggest a threshold value ~ 45 nM.

The GM Ctrough in study 022 decreased with decreasing age, while there was no consistent trend for the GM AUC.

Although the GM Ctrough in study 022 was lower in cohort IIB compared to cohort IIA, the number and proportion with AUC &lt; 14 nM was not higher in the cohorts that received 6 mg/kg using chewable tablets vs. the Cohorts that received adult tablets. Likewise, the number of patients with Ctrough &lt; 45 nM were comparable. Hence, the two formulations (chewable tablets and tablets) were considered suitable for the age range 6 to 11 years.

However, due to the very limited sample size in this trial, some uncertainties remained during the application regarding the downward trend in mean Ctrough levels with decreasing age and the applicability of the target minimum Ctrough to young children, who may have high viral loads before starting a RAL-containing regimen. Hence, the applicant was invited to an Oral Explanation during the September CHMP meeting.

During this meeting, satisfactory clarification and reassurance were provided by the applicant. Indeed, based on the Ctrough threshold of ~45 nM, the intensive sampling data and the CV% values support the dosing recommendations, regardless of the fact that GM Ctrough derived from intensive sampling drifts downwards with decreasing age. The individual numbers with Ctrough &lt; 45 nM were 0-2 per age group/dose cohort as summarised in Table 5. Focusing on the Ctrough comparisons, neither the intensive nor the (calculation-corrected) sparse sampling Ctrough suggest that there would be a higher risk of values below 33 (or even 45) nM when using the chewable tablets from the age of 2 years compared with other age group / dose cohort.

The need for Therapeutic Drug Monitoring (TDM) in children aged 2 to 6 years was discussed during the Oral Explanation; however, the CHMP considered that TDM wasn't required to monitor the exposure in this population.

Given the limited number of patients enrolled in this paediatric study 022, the CHMP requested the applicant to collect additional data in children aged 2 to &lt;6 years of age to provide further data on the adequacy of the recommended posology with particular reference to the threshold value of Ctrough ~ 45nM.

The applicant will therefore collect additional PK information through a sub study of IMPAACT P1066. In approximately 10 patients receiving chewable tablets, who may have enrolled in study P022 to receive the oral granules formulation, Ctrough from non-observed dosing (11-13 hrs post dose) would be obtained.  These data are expected with the coming application presenting the results of study P022 in the younger age group (i.e. 4 weeks to 2 years of age). This information will be especially relevant for children who may have high viral loads before starting a RAL-containing regimen.

<div style=\"page-break-after: always\"></div>

Should the actual data suggest a substantial risk that levels fall below 45 nM then the CHMP will consider the need to modify the prescribing information and/or request further data from this age cohort. The applicant could also explore a different dose regimen (e.g. 4mg/kg TID as suggested by the applicant during the oral explanation).

## 2.4.5. Conclusions on clinical pharmacology

Data from study P022 support the recommendation to use a fixed dose of the adult formulation 400 BID when body weight is ≥ 25 kg in children aged 6 to 18 years and a weight based regimen of 6mg/kg, to maximum dose 300 mg, twice daily, of the chewable tablets when body weight is ≥ 12 kg in children aged 2 to 12 years. Administration of raltegravir was allowed without regard to food intake during most of study P022 as no significant food effect has been detected with the various raltegravir formulations; hence, the SmPC states that raltegravir can be used with or without food.

Based on the Ctrough threshold of ~45 nM, the intensive sampling data and the CV% values support the dosing recommendations. Further data are awaited from the applicant to prospectively assess the relationship between Ctrough values and viral load in younger children.

## 2.5. Clinical efficacy

## 2.5.1. Main study

Study 022 (P1066; IMPAACT) is an on-going Phase I/II, multi-center, open-label, non-comparative study of approximately 140 HIV-1 infected children and adolescents 4 weeks through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen.

## Study Participants

HIV-1 infection was defined as positive results from two samples (blood, serum or plasma) collected at different time points and the tests that were to be used were defined in the protocol by age group.

Eligibility for any of Cohorts I, IIA, IIB and III required that the patient had been on an unchanged therapeutic regimen for at least 12 weeks or were treatment experienced but had not been on treatment for ≥ 4 weeks prior to study entry.

Dose adjustments for growth, formulation substitutions and substitutions within class for toxicity management within the prior 12 weeks were permitted.

Subjects must have had ≤ 1 log drop in HIV RNA within 12 weeks prior to the screening visit or screening HIV RNA ≥ 25,000 copies/mL (with the exception of patients who had not received ARV therapy for ≥ 4 weeks prior to entry). HIV RNA was to be ≥ 1,000 copies/mL at the screening visit.

## Treatments

See section 2.4.2 for details on raltegravir treatment. The content of the OBT could be changed during the study provided this was confined to substitution within class (rarely across class for documented toxicity), discontinuation of a background ARV or formulation substitutions.

<div style=\"page-break-after: always\"></div>

## Objectives

- Stage I: to evaluate the short term safety of raltegravir in infants, children and adolescents and to evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of raltegravir in infants, children and adolescents.
- Stage II: to evaluate the safety and tolerability of raltegravir at the selected dose in combination with OBT in children and adolescents in the age groups defined by Cohort.

## Outcomes/endpoints

P1066 was not designed or powered to demonstrate efficacy. However, efficacy measurements included HIV RNA, CD4 cell counts and percentages and viral resistance testing. The mode of testing and quantifying HIV RNA was defined in the protocol and was primarily based on testing by local CLIAcertified (or equivalent) laboratories using the AMPLICOR HIV-1 MONITOR Test (Version 1.5), ultrasensitive method. For all patients, blood samples for viral resistance assays were collected at screening and subsequently at Weeks 12, 24, 36 and 48 and at time of failure.

## Sample size

There were no hypotheses for this study.

## Statistical methods

The All Treated population included all enrolled patients who received any dose of raltegravir.

The Final Dose population included patients who received only the final selected dose, whether enrolled in Stage I or Stage II. This population was considered the evaluable population and was used for the primary assessment of safety and efficacy since the data are most relevant to the intended commercial use.

For each of the defined virological responses (successes), the following two approaches were used to handle missing values for patients who prematurely discontinued assigned treatment:

- Observed Failure (OF): Patients who prematurely discontinued assigned treatment due to lack of efficacy were considered as failures thereafter. Patients who prematurely discontinued assigned treatment, for reasons other than lack of efficacy, were excluded from the analyses.
- Non-Completer = Failure (NC=F): Patients who prematurely discontinued assigned treatment regardless of reasons were considered as failures thereafter. Intermittent missing values were assigned as failures unless immediately flanked by 2 successes.

## Definition of virological failure

To distinguish non-response from rebound, the final definition of virological failure was as follows:

- 1) never achieved ≥ 1 log drop from baseline in plasma HIV RNA or HIV RNA &lt; 400 copies/mL through Week 24

OR

- 2) virological rebound at Week 24 or later defined as (a) confirmed HIV RNA ≥ 400 copies/mL (on 2 consecutive measurements at least 1 week apart) after initial response with HIV RNA &lt; 400 copies/mL or (b) confirmed &gt; 1.0 log10 increase in HIV RNA above nadir level (on 2 consecutive measurements at least 1 week apart). Nadir was defined as the lowest HIV RNA by the evaluated time point.

<div style=\"page-break-after: always\"></div>

## Analysis by Demographic and Prognostic Factors

The protocol specified that logistic/linear regression model would be used to identify variables contributing to virological success and favourable CD4 changes. The analysis of efficacy by PK parameters used the average raltegravir concentration from each patient's random PK measures as a covariate in predicting virological outcome at Week 24. The specific background regimen was not used as a prognostic factor because of the sparse use of various different regimens.

## Results

## Participant flow

Figure 6. Schematic of Study 022 (15 July 2011)

<!-- image -->

## Recruitment

Patients were enrolled at 40 of the 56 study sites that were initiated across North and South America and Southern Africa. The majority of patients in Cohorts I, IIA and IIB were enrolled in the US while the majority of patients in Cohort III (≥ 2 through &lt; 6 years of age) were enrolled in South Africa and Brazil.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 6. Baseline Characteristics and Efficacy Outcomes at Weeks 24 and 48 from IMPAACT P1066

| Parameter                                         | Final Dose Population N=96   |
|---------------------------------------------------|------------------------------|
| Demographics                                      |                              |
| Age (years), median [range]                       | 13 [2 - 18]                  |
| Male Gender                                       | 49%                          |
| Race                                              |                              |
| Caucasian                                         | 34%                          |
| Black                                             | 59%                          |
| Baseline Characteristics                          |                              |
| Plasma HIV-1 RNA (log 10 copies/ml), mean [range] | 4.3 [2.7 - 6)]               |
| CD4 cell count (cells/mm 3 ), median [range]      | 481 [0 - 2361]               |
| CD4 percent, median [range]                       | 23.3 %[0 - 44]               |
| HIV-1 RNA >100,000 copies/ml                      | 8%                           |
| CDC HIV category B or C                           | 59%                          |
| Prior ART Use by Class                            |                              |
| NNRTI                                             | 78%                          |
| PI                                                | 83%                          |

## Numbers analysed

A cumulative total of 126 patients (All Treated population) were enrolled and treated in Cohorts I, IIA, IIB and III, as of the data cutoff of 15-Jul-2011, including 87 patients in the adult tablet formulation group (Cohort I and IIA) and 39 patients in the chewable tablet formulation group (Cohort IIB and III).

## Outcomes and estimation

## Efficacy

P1066 was not designed or powered to demonstrate efficacy.

Based upon the OF approach &gt; 70% of the patients in each cohort had ≥ 1 log drop in HIV RNA or HIV RNA &lt; 400 copies/mL at Week 24 except for Cohort IIA (with only 4 patients in the Final Dose population and a response rate of 50%).

At Week 24 all Cohort IIB and III patients had complete data. Based on the OF approach in the final dose population, 76.9% (10/13) and 70% (14/20) in respective cohorts had ≥ 1 log drop from baseline in HIV RNA or &lt; 400 copies/mL at Week 24 while 53.8% (7/13) and 50% (10/20) achieved &lt; 50 copies/mL.  Mean change from baseline in CD4 cell count was &gt; 140 cells/mm 3  for all 33 children and the mean change in CD4% from baseline was 3.5% (0.8% in Cohort IIB and 5.3% in Cohort III).

AUC0-12hr and C12hr values by age and weight showed that the final dosing recommendations for each cohort (I, IIA, IIB, and III) resulted in consistent and acceptable (based on the protocol pre-defined values) estimates for AUC0-12hr and C12hr across the entire ranges of age (2 to 18 years) and weights (12 to 60 kg).

<div style=\"page-break-after: always\"></div>

Table 7. Efficacy analysis by cohort; final dose population; week 24; observed failure approach

| Parameter                                                                                     | (N=59)   | (N=59)            | Cohort IIA (N=4)   | Cohort IIA (N=4)   | Cohort IIB (N=13)   | Cohort IIB (N=13)   | Cohort III (N=20)   | Cohort III (N=20)   | Total (N=96)   | Total (N=96)      |
|-----------------------------------------------------------------------------------------------|----------|-------------------|--------------------|--------------------|---------------------|---------------------|---------------------|---------------------|----------------|-------------------|
|                                                                                               | n/N      | % (95% CI)        | n/N                | % (95% CI)         | n/N                 | % (95% CI)          | n/N                 | % (95% CI)          | n/N            | % (95% CI)        |
| Proportion of patients with >=1 log10 drop from baseline in HIV RNA or HIV RNA <400 copies/mL | 42/58    | 72.4 (59.1, 83.3) | 2/4                | 50 (6.8, 93.2)     | 10/13               | 76.9 (46.2, 95)     | 14/20               | 70 (45.7, 88.1)     | 68/95          | 71.6 (61.4, 80.4) |
| Proportion of patients with HIV RNA <50 copies/mL                                             | 32/58    | 55.2 (41.5, 68.3) |                    | 50 (6.8, 93.2)     | 7/13                | 53.8 (25.1, 80.8)   | 10/20               | 50 (27.2, 72.8)     | 51/95          | 53.7 (43.2, 64)   |
| Proportion of patients with HIV RNA <400 copies/mL                                            | 40/58    | 69 (55.5, 80.5)   |                    | 50 (6.8, 93.2)     | 9/13                | 69.2 (38.6, 90.9)   | 12/20               | 60 (36.1, 80.9)     | 63/95          | 66.3 (55.9, 75.7) |
|                                                                                               | Mean     | (95% CI)          | Mean               | (95% CI)           | Meam                | (95% CI)            | Mean                | (95% CI)            | Mean           | (95% CI)          |
| Change from baseline in CD4 cell count (cells/mm3)                                            | 114.4    | (73.7, 155.1)     | -35.8              | (-348.8, 277.3)    | 143.4               | (-12.9, 299.6)      | 147.2               | (-2.7, 297.1)       | 119.0          | (74.9, 163.1)     |
| Change from baseline in CD4 percent                                                           | 4.1      | (2.8, 5.3)        | 2.2                | (-7.2, 11.5)       | 0.8                 | (-3.6, 5.2)         | 5.3                 | (2.9, 7.7)          | 3.8            | (2.7, 4.9)        |

N = Number of patients in each cohort.

For continuous endpoints: mean change with (95% CI) was reported. Normal distributions were assumed for continuous endpoints.

For binary endpoints: n/N with % (95% CI) was reported for each cohort, where n/N=uuber of responders/ntuber of patients.

Observed Failure Approach for handling missing data: -For binary endpoints, missing values were considered as failures for patients missing data due to discontinmuation of study treatment for lack of effcacy or for non-treatment related reasons with last available HIV RNA

-For continuous endpoints (e.g. change from baseline in CD4 cell counts and percent), baseline values were camied forward for patients missing data due to discontinuation of study treatment for lack of efficacy or for non-treatment related reasons with last available HIV RNA value &lt; 1 log10 drop from baseline and &gt;=400 copies/mL; otherwise patients with missing values were evcluded.

value &lt; 1 log10 drop from baseline and &gt;=400 copies/mL; otherwise patients with missing values were excluded.

The results for the All Treated population were generally comparable to those for the Final Dose population. With more patients included in All Treated population for Cohort IIA (N=16), the viral and CD4 responses in this cohort were more consistent with the other cohorts.

The Week 48 results showed a similar pattern those for Week 24. There was a slight increase in overall proportions with a virological response and a larger increase in CD4 cell count and CD4 percent. Again, the results for the All Treated patients at Week 48 were comparable to those for the Final Dose population.

Table 8. Efficacy analysis by cohort; final dose population; week 48; observed failure approach

| Parameter                                                                                     | CohortI (N=59)   | CohortI (N=59)    | Cohort IIA (N=4)   | Cohort IIA (N=4)   | Cohort IIB (N=13)   | Cohort IIB (N=13)   | Total (N=76)   | Total (N=76)      |
|-----------------------------------------------------------------------------------------------|------------------|-------------------|--------------------|--------------------|---------------------|---------------------|----------------|-------------------|
|                                                                                               | N/               | % (95% CI)        | nN                 | % (95% CI)         | n/N                 | % (95% CI)          | n/N            | % (95% CI)        |
| Proportion of patients with >=1 log10 drop from baseline in HIV RNA or HIV RNA <400 copies/mL | 42/56            | 75 (61.6, 85.6)   | 3/4                | 75 (19.4, 99.4)    | 10/11               | 90.9 (58.7, 99.8)   | 55/71          | 77.5 (66, 86.5)   |
| Proportion of patients with HIV RNA <50 copies/mL                                             | 32/56            | 57.1 (43.2, 70.3) | 2/4                | 50 (6.8, 93.2)     | 6/11                | 54.5 (23.4, 83.3)   | 40/71          | 56.3 (44, 68.1)   |
| /satdos 00t> VNH AIH wIM saed po topiodond                                                    | 39/56            | 69.6 (55.9, 81.2) | 2/4                | 50 (6.8, 93.2)     | 10/11               | 90.9 (58.7, 99.8)   | 51/71          | 71.8 (59.9, 81.9) |
|                                                                                               | Mean             | (95% CI)          | Mean               | (95% CI)           | Mean                | (95% CI)            | Mean           | (95% CI)          |
| Change from baseline in CD4 cell coumt (cells/mm3)                                            | 168.2            | (117.5, 218.9)    | 189.5              | (-154.2, 533.2)    | 76.8                | (-85.3, 238.9)      | 155.1          | (107.9, 202.2)    |
| Change from baseline in CD4 percent                                                           | 5.2              | (3.9, 6.6)        | 6.0                | (-2.6, 14.6)       | 1.6                 | (-2.7, 5.9)         | 4.7            | (3.4, 6)          |

N = Number of patients in each cohort.

sodpa sno nog pamsse anan smstp e pnodan sem  s6)rm am tea suoda snonmos o

For binary endpoints: n/N with % (95% CI) was reported for each cohort, where n/N=mummber of responders/mumber of patients.

-For binary endpoints, missing values were considered as failures for patients missing data due to discontinuation of study treatment for lack of efficacy or for non-treatment related reasons with last available HIV RNA

non-treatment related reasons with last available HIV RNA value &lt; 1 log10 drop from baseline and &gt;=400 copies/mL; otherwise patients with missing values were excluded

value &lt; 1 log10 drop from baseline and &gt;=400 copies/mL; otherwise patients with missing values were excluded. -For continuous endpoints (e.g. change from baseline in CD4 cell coumts and percent), baseline values were carried forward for patients missing data due to discontimuation of study treatment for lack of efficacy or for

The results obtained when the NC=F approach was used in the Final Dose and All Treated populations were generally comparable to those observed using the primary OF missing data approach.

From Week 4 onwards over 80% of patients in each cohort achieved ≥ 1 log10 drop from baseline in HIV RNA or HIV RNA &lt; 400 copies/mL. Between Weeks 12 and 24 there were small drops in percentages meeting the primary virological response criteria. Patients in Cohorts I, IIB and III achieved similar virological suppression over time with sustained responses up to Weeks 24 and 48. At Week 80, the success rate for Cohort I patients was &gt; 60%. Cohort IIA (N=4) had a response rate comparable to other cohorts through Week 12 but by Week 24 two experienced an increase in HIV RNA although another regained suppression by Week 48. The data were also shown separately for those with &lt; 400 copies/mL over time, with a similar pattern observed.

At Week 8, 59% of all patients achieved HIV RNA &lt; 50 copies/mL. Sustained responses were observed until Week 24 for each cohort and up to Week 48 for Cohorts I, IIA and IIB. At Week 80 45% of Cohort I patients had HIV RNA &lt;50 copies/mL.

<div style=\"page-break-after: always\"></div>

In the All Treated population 25 patients across all cohorts failed by Week 24 and 34 patients failed by Week 48. Most failures involved rebound and there were very few non-responders. Most failures that occurred between Weeks 24 and 48 (7/9) were in Cohort I.

## Treatment adherence

In cohort IIB, 33.3% of patients were 100% compliant, 11.1% of patients were 99 to 90% compliant and 22.2% of patients were 89 to 80% compliant. In cohort III, 33.3% of patients were 100% compliant, 42.9% of patients were 99 to 90% compliant and 14.3% of patients were 89 to 80% compliant (all treated population; DLP 14/02/11). One patient in Cohort IIB was reported to have discontinued due to intolerance. No patient in Cohort III discontinued the chewable tablet due to palatability issues. However, it should be noted that treatment adherence data were not reliable as these were not available for every patient or every time point during the treatment period.

No clear relationship was detected between adherence and failure but again this result may be unreliable due to the considerable amount of missing data on pill counts.

## Resistance

Of the 34 All Treated patients with virological failure 18 (53%) had at least 1 BLOQ PK sample and 10 (29%) had ≥ 2 BLOQ PK samples. However, none of the patients in the Final Dose population that failed and had a virus showing acquired resistance had BLOQ PK samples.

Patients had not been exposed to raltegravir or an experimental integrase inhibitor prior to enrolment. Viruses isolated in screening visit samples from patients who ultimately failed included: one with T97A that was phenotypically sensitive, two with L741, both phenotypically sensitive, one with I203 M that was phenotypically sensitive. All other baseline viruses either showed no known raltegravir RAMs or the results are not available.

Of the 31 All Treated patients who failed and had any genotypic data available, viruses obtained at the time of failure from 10 (32.3%) displayed signature resistance mutations as shown below.

Table 9. Number (%) of virologic failure patients with HIV integrase mutations at amino acids 143, 148 and/or 155 by cohort; all treated population; weeks 0-48

|                                                      | Cohort I (N=18) n (%)   | Cohort IIA (N=6) n (%)   | CohortIIB (N=4) n (%)   | Cohort III (N=3) n (%)   | Total (A11 Cohorts) (N=31) n (%)   |
|------------------------------------------------------|-------------------------|--------------------------|-------------------------|--------------------------|------------------------------------|
| Number (%) With Mutation at Amino Acid 143,148or 155 | 2 (11.1)                | 4 (66.7) 1 (16.7)        | 2 (50.0)                | 2 (66.7)                 | 10 (32.3)                          |
| WithMutation atAminoAcid143                          | 0 (0)                   |                          | 0 (0)                   | 0 (0)                    | 1 (3.2)                            |
| WithMutationY143C                                    | 0 (0)                   | 0 (0)                    | 0 (0)                   | 0 (0)                    | 0 (0)                              |
| WithMutationY143H                                    | 0 (0)                   | 0 (0)                    | 0 (0)                   | 0 (0)                    | 0 (0)                              |
| WithMutationY143R                                    | 0 (0)                   | 1 (16.7)                 | 0 (0)                   | 0 (0)                    | 1 (3.2)                            |
| WithMutation atAminoAcid148                          | 1 (5.6)                 | 3 (50.0)                 | 1 (25.0)                | 2 (66.7)                 | 7 (22.6)                           |
| WithMutationQ148H                                    | 1 (5.6)                 | 1 (16.7)                 | 1 (25.0)                | 0 (0)                    | 3 (9.7)                            |
| WithMutation Q148K                                   | 0 (0)                   | 0(0)                     | 0 (0)                   | 0 (0)                    | 0 (0)                              |
| WithMutation Q148R                                   | 0 (0)                   | 2 (33.3)                 | 0 (0)                   | 2 (66.7)                 | 4 (12.9)                           |
| WithMutationatAminoAcid155                           | 2 (11.1)                | 1 (16.7)                 | 1 (25.0)                | 1 (33.3)                 | 5 (16.1)                           |
| With NoMutation ateitherAminoAcid143,148or155        | 16 (88.9)               | 2 (33.3)                 | 2 (50.0)                | 1 (33.3)                 | 21 (67.7)                          |
| With OtherKnownRALResistanceMutations                | 2 (11.1)                | 0 (0)                    | 0 (0)                   | 0 (0)                    | 2 (6.5)                            |
| WithNoOtherKnownRALResistanceMutations               | 14 (77.8)               | 2 (33.3)                 | 2 (50.0)                | 1 (33.3)                 | 19 (61.3)                          |

HIV Integrase resistance mutations were identified by the Monogram Biosciences,Inc. GeneSeq Integrase Genotypic Test.

N =Number of virologic failure patients with integrase mutation test done in each cohort.

CompleteWeek 48data isavailablefor52.4%(11/21)of CohortII.

<div style=\"page-break-after: always\"></div>

Two of the 21 virological failures whose viruses did not display a primary raltegravir resistance mutation at the time of failure had viruses containing other known raltegravir resistance mutations.

Among the All Treated patients who failed by Week 48, there were 26 patients with both baseline and post-baseline phenotypic resistance data. Viruses from these patients at baseline showed phenotypic susceptibility. Viruses obtained after virological failure showed mean and median fold-changes in IC50 of 33.8 and 1.0 (range 0.6 to 150.2), respectively.

Virological response rates were broadly consistent across race, ethnicity, baseline HIV RNA category, baseline CD4 cell count category, viral subtype and number of classes of ARV drugs previously exposed. The response rate for male patients was 22.6% higher than that for females and response rates for patients with fewer than 2 active drugs in their OBT based on PSS and GSS were higher (by 20.6% and 29.2%, respectively) than those with 2 or more active drugs in OBT. The response rate was slightly higher in those with higher viral load at baseline and for non-clade B virus. However, it should be noted that the number analysed are relatively small.

## GSS / PSS

Analyses using the univariate logistic regression model showed that gender and GSS had significant associations with the virological response. The PSS effect was in the same direction as the GSS effect but was not as strong. This model did not control for confounding of associations by other covariates.

## Summary of main study

The following tables summarise the results from the main studies supporting the present application. These summaries should be read in conjunction with the discussions as well as the benefit risk assessment.

Table 10. Summary of Efficacy for trial IMPAACT P1066 (Merck P022)

| Title : Phase I/II, multi-center, open-label, non-comparative study in HIV-1 infected children and adolescents 2 years through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen   | Title : Phase I/II, multi-center, open-label, non-comparative study in HIV-1 infected children and adolescents 2 years through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen            | Title : Phase I/II, multi-center, open-label, non-comparative study in HIV-1 infected children and adolescents 2 years through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                     | Study 022 (IMPAACT P1066 )                                                                                                                                                                                                                                                                    | Study 022 (IMPAACT P1066 )                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                                               | Phase I/II, multi-center, open-label, non-comparative study of approximately 140 HIV-1 infected children and adolescents 2 years through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen. | Phase I/II, multi-center, open-label, non-comparative study of approximately 140 HIV-1 infected children and adolescents 2 years through 18 years of age to evaluate the safety, tolerability, PK parameters and efficacy of raltegravir in combination with an optimized background regimen. |
| Design                                                                                                                                                                                                                                                                               | Duration of main phase: Duration of Extension phase:                                                                                                                                                                                                                                          | 24 weeks (primary), 48 weeks (secondary) 4 years (total study duration 240 weeks)                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                                                                                                                           | No hypotheses were specified.                                                                                                                                                                                                                                                                 | No hypotheses were specified.                                                                                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                                                                                                    | Film-coated tablets                                                                                                                                                                                                                                                                           | Raltegravir adult tablet 400 mg b.i.d + optimized background regimen for patients 6- 18 years old                                                                                                                                                                                             |
| Treatments groups                                                                                                                                                                                                                                                                    | Chewable Tablet                                                                                                                                                                                                                                                                               | Raltegravir chewable tablet approximately 6mg/kg b.i.d + optimized background regimen for patients 2-11 years old                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Objectives   | Stage I: to evaluate the short term safety of raltegravir in infants, children and adolescents and to evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of raltegravir in infants, children and adolescents. Stage II: to evaluate the safety and tolerability of raltegravir at the selected dose in combination with OBT in children and adolescents in the age groups defined by Cohort. Note: P1066 was not designed or powered to demonstrate efficacy.   |
|-----------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Results and Analysis

| Pharmacokinetics   | Age                                                             | Formulation                                                     | Formulation                                                     | Dose                                                            | Number of subjects (Intensive PK)                               | Geometric Mean (%CV) AUC 0- 12hr (μM*hr)                        | Geometric Mean (%CV) C12hr (nM)                                 |
|--------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Pharmacokinetics   | 12 through 18 years                                             | Film-coated tablets                                             | Film-coated tablets                                             | 400 mg twice daily, regardless of weight                        | 11                                                              | 15.7 (98 %)                                                     | 333 (78 %)                                                      |
| Pharmacokinetics   | 6 through 11 years                                              | Film-coated tablets                                             | Film-coated tablets                                             | 400 mg twice daily, for patients ≥25 kg                         | 11                                                              | 15.8 (120 %)                                                    | 246 (221 %)                                                     |
| Pharmacokinetics   | 6 through 11 years                                              | Chewable tablet                                                 | Chewable tablet                                                 | Weight based dosing                                             | 10                                                              | 22.6 (34 %)                                                     | 130 (88 %)                                                      |
| Pharmacokinetics   | 2 through 5 years                                               | Chewable tablet                                                 | Chewable tablet                                                 | Weight based dosing                                             | 12                                                              | 18.0 (59 %)                                                     | 71 (55 %)                                                       |
| Safety             | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. | The safety data did not give rise to any new or major concerns. |
| Efficacy           | Time point                                                      | Time point                                                      | 24 weeks                                                        | 24 weeks                                                        | 48 weeks                                                        | 48 weeks                                                        | 48 weeks                                                        |
| Efficacy           | Number of subject                                               | Number of subject                                               | 96                                                              | 96                                                              | 96                                                              | 96                                                              | 96                                                              |
| Efficacy           | Achieved ≥1 log10 HIV RNA drop from baseline or <400 copies/mL  | Achieved ≥1 log10 HIV RNA drop from baseline or <400 copies/mL  | 72%                                                             | 72%                                                             | 79%                                                             | 79%                                                             | 79%                                                             |

## 2.5.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant has broadly complied with the advice given on paediatric development in the CHMP guideline on the clinical development of medicinal products for the treatment of HIV infection (Doc. Ref. EMEA/CPMP/EWP/633/02).

## Efficacy data and additional analyses

The changes in CD4 cell counts and percentages over time demonstrated comparable patterns across the cohorts except for Cohort IIA, which had large variability due to the small sample size. The results for the All Treated population were comparable to those for the Final Dose population. Change from

<div style=\"page-break-after: always\"></div>

baseline in HIV RNA at Week 24 and virological success at Week 24 were significantly correlated with Week 24 CD4 cell count change.

## 2.5.3. Conclusions on the clinical efficacy

In line with the CHMP guideline on the clinical development of medicinal products for the treatment of HIV infection (Doc. Ref. EMEA/CPMP/EWP/633/02), based on the identification of suitable dose regimens and the expectation that PK/PD relationships are the same in children as in adults, an extrapolation of efficacy data obtained in adults to children may be accepted.

As per the above, Study P022 has been designed accordingly and therefore efficacy wasn't a primary endpoint. The numbers per cohort and in the various sub-groups of interest are too small to draw definite conclusions, but taking into account the overall virological and immunological response rates in study P022 which were satisfactory, the CHMP concludes that the extrapolation was appropriate to the paediatric population covered by the proposed indication.

## 2.6. Clinical safety

## Patient exposure

All patients who received at least one dose of raltegravir in study 022 were included in the evaluation of safety. Patients who switched raltegravir formulations during the study were included with their originally assigned age cohort and formulation for safety reporting.

- The mean number of days (range) for Final Dose patients on any dose of raltegravir was 565 (28 to 1112) days. The mean number of days (range) for All Treated patients on raltegravir at any dose was 626 (28 to 1246) days.
- The mean number of days (range) for Cohort I and IIA (tablet) Final Dose patients on raltegravir tablets at 400 mg BID was 657 (28 to 1112) days. Over 40 patients in Cohort I had received raltegravir for more than 96 weeks by the cut-off date for the CSR.
- The mean number of days on raltegravir for Cohorts IIB and III (chewable tablet) was 351 (179 to 604) days. Total daily doses were weight-based and ranged from 75 to 300 mg twice daily.

## Adverse events

Final Dose, Weeks 0-24

<div style=\"page-break-after: always\"></div>

Table 11. Summary of clinical AE by cohort; final dose population; weeks 0-24

|                                                                     | Cohort I (N=59) n (%)   | Cohort IIA (N=4) n (%)   | CohortIIB (N=13) n (%)   | Cohort II (N=20) n (%)   | Total (N=96) n (%)   |
|---------------------------------------------------------------------|-------------------------|--------------------------|--------------------------|--------------------------|----------------------|
| With one or more clinical adverse events                            | 50 (84.7)               | 3 (75)                   | 10 (76.9)                | 14 (70)                  | 77 (80.2)            |
| Withno clinicaladverse event                                        | 9 (15.3)                | 1 (25)                   | 3 (23.1)                 | 6 (30)                   | 19 (19.8)            |
| With one or more serious clinical adverse events                    | 9 (15.3)                | 0 (0)                    | 2 (15.4)                 | 2 (10)                   | 13 (13.5)            |
| Withone ormore serious drugrelatedfclinical adverse events          | (0) 0                   | (0) 0                    | 0 (0)                    | 1(5)                     | 1 (1)                |
| Who died due to clinicaladverse events                              | 0 (0)                   | (0) 0                    | 0 (0)                    | 0 (0)                    | 0 (0)                |
| Discontinued due to an adverse event(clinicalorlaboratory)          | 0 (0)                   | (0) 0                    | 0 (0)                    | 0 (0)                    | 0 (0)                |
| With one or more Grade 3 or greater clinical adverse events         | 8 (13.6)                | 0(0)                     | 2 (15.4)                 | 3 (15)                   | 13 (13.5)            |
| With one ormore Grade3or greater drugrelatedclinical adverse events | 1 (1.7)                 | 0 (0)                    | 0 (0)                    | (0) 0                    | 1(1)                 |

N =Number of patients in each cohort.

n (%) =Number (percent) of patients in each subcategory.

Drug related adverse events were determined by the investigator to be possibly, probably or definitely related to raltegravir.

Events were included if they occurred while on study drug or within 14 days after discontinuation of study drug.

The most frequently reported AEs were cough (32.3%), pyrexia (24%) and rhinorrhoea (18.8%). The profile of AEs for All Treated patients was generally similar to that for Final Dose patients.

The most frequently reported AEs of Grade 3 or greater were various pneumonias [7.3% Final Dose patients; including bronchopneumonia (1), lobar pneumonia (1), pneumonia (3), pneumococcal pneumonia (1) and RSV pneumonia (1)], pyrexia (2.1%), gastroenteritis (2.1%) and suicidal behaviour (2.1%). Only three Grade 3 or greater AEs (in one patient) were considered drug-related (events of abnormal behaviour, psychomotor hyperactivity and insomnia).

## Final Dose, Weeks 0-48

Clinical AEs (Grades 1-4) were reported by 85.4% of Final Dose patients up to Week 48. The profile of clinical adverse events at Week 48 was generally similar to that at Week 24 for Final Dose patients. The most frequently reported were cough (42.7%), pyrexia (32.3%), and rhinorrhoea (27.1%).

Table 12. Summary of clinical AE by cohort; final dose population; weeks 0-48

|                                                                          | CohortI (69=N) n (%)   | CohortILA (N=4) (%)u   | Cohort IB (N=13) (%)   | Cohort (N=20) n (%)   | Total (96=N) n (%)   |
|--------------------------------------------------------------------------|------------------------|------------------------|------------------------|-----------------------|----------------------|
| With one or more clinical adverse events                                 | 53 (89.8)              | 4 (100)                | 11 (84.6)              | 14 (70)               | 82 (85.4)            |
| With no climical adverse event                                           | 6 (10.2)               | 0 (0)                  | 2 (15.4)               | 6 (30)                | 14 (14.6)            |
| With one or more serious clinical adverse events                         | 10 (16.9)              | 0 (0)                  | 2 (15.4)               | 2 (10)                | 14 (14.6)            |
| With one or more serious diug related clinical adverse events            | (0) 0                  | 0 (0)                  | 0 (0)                  | 1 (5)                 | 1 (1)                |
| Who died due to clinical adverse events                                  | (0) 0                  | 0 (0)                  | 0 (0)                  | 0 (0)                 | 0 (0)                |
| Discontinued due to an adverse event (clinical or laboratory)            | (0)0                   | 0 (0)                  | 0 (0)                  | 0 (0)                 | 0 (0)                |
| With one or more Grade3 or greater clinical adverse events               | 10 (16.9)              | 0 (0)                  | 2 (15.4)               | 3 (15)                | 15 (15.6)            |
| With one or more Grade 3 or greater drug related clinical adverse events | 1 (1.7)                | 0 (0)                  | (0)0                   | 0 (0)                 | 1 (1)                |

<div style=\"page-break-after: always\"></div>

Table 13. All clinical AE by cohort (incidence ≥10% in one or more cohorts); final dose population; weeks 0-48

|                                                  | CohortI (N=59)   | Cohort IIA (N=4)   | Cohort IIB (N=13)   | Cohort III (N=20)   | Total (96=N)   |
|--------------------------------------------------|------------------|--------------------|---------------------|---------------------|----------------|
| System Organ Class Preferred Term                | n (%)            | n (%)              | n (%)               | n (%)               | (%)            |
| Numberofpatientswithone ormore adverse events    | 53 (89.8)        | 4 (100)            | 11 (84.6)           | 14 (70)             | 82 (85.4)      |
| Blood and lymphatic system disorders             | 7 (11.9)         | 0 (0)              | 1 (7.7)             | 6 (30)              | 14 (14.6)      |
| Lymphadenopathy                                  | 6 (10.2)         | 0 (0)              | 0(0)                | 6 (30)              | 12 (12.5)      |
| Ear and labyrinth disorders                      | 11 (18.6)        | 0(0)               | 1 (7.7)             | 3 (15)              | 15 (15.6)      |
| Ear pain                                         | (E'S1) 6         | 0 (0)              | 1 (7.7)             | 1 (5)               | 11 (11.5)      |
| Otorrhoea                                        | 2 (3.4)          | 0 (0)              | 0 (0)               | 2 (10)              | 4 (4.2)        |
| Eye disorders                                    | 8 (13.6)         | 0(0)               | 1 (7.7)             | 0(0)                | 9 (9.4)        |
| Gastrointestinal disorders                       | 33 (55.9)        | 1 (25)             | 4 (30.8)            | 7 (35)              | 45 (46.9)      |
| Abdominal pain                                   | 8 (13.6)         | 1 (25)             | 1 (7.7)             | 0(0)                | 10 (10.4)      |
| Abdominal pain upper                             | 7 (11.9)         | 0 (0)              | 0 (0)               | 0(0)                | 7 (7.3)        |
| Breath odour                                     | 1 (1.7)          | 0 (0)              | 2 (15.4)            | (0) 0               | 3 (3.1)        |
| Diarrhoea                                        | 9 (15.3)         | 0 (0)              | 0 (0)               | 4 (20)              | 13 (13.5)      |
| Nausea                                           | 11 (18.6)        | 0 (0)              | 0(0)                | 0(0)                | 11 (11.5)      |
| Vomiting                                         | 14 (23.7)        | 0 (0)              | 1 (7.7)             | 5 (25)              | 20 (20.8)      |
| Generaldisordersand administrationsiteconditions | 22 (37.3)        | 1 (25)             | 6 (46.2)            | 6 (30)              | 35 (36.5)      |
| Pyrexia                                          | 18 (30.5)        | 1 (25)             | 6 (46.2)            | 6 (30)              | 31 (32.3)      |
| Hepatobiliary disorders                          | (0) 0            | (0) 0              | 0(0)                | 3 (15)              | 3 (3.1)        |
| Hepatomegaly                                     | (0) 0            | 0(0)               | 0 (0)               | 3 (15)              | 3 (3.1)        |
| Infections and infestations                      | 27 (45.8)        | (0) 0              | 10 (76.9)           | 12 (60)             | 49 (51)        |
|                                                  |                  |                    | 3 (23.1)            |                     | 7 (7.3)        |
| Gastroenteritis                                  | 2 (3.4)          | 0 (0)              |                     | 2 (10)              |                |
| Impetigo                                         | (0) 0            | 0 (0)              | 0 (0)               | 3 (15)              | 3 (3.1)        |
| Oral herpes                                      | (0) 0            | 0(0)               | 2 (15.4)            | 2 (10)              | 4 (4.2)        |
| Otitis media                                     | 2 (3.4)          | 0 (0)              | 1 (7.7)             | 5 (25)              | 8 (8.3)        |
| Sinusitisbacterial                               | (0) 0            | 0 (0)              | 2 (15.4)            | 1(5)                | 3 (3.1)        |
| Tonsillitis                                      | (0) 0            | 0 (0)              | 0 (0)               | 2 (10)              | 2 (2.1)        |
| Metabolism and nutrition disorders               | 3 (5.1)          | 0 (0)              | 1 (7.7)             | 2 (10)              | 6 (6.3)        |
| Musculoskeletal and connective tissue disorders  | 15 (25.4)        | 0(0)               | 1 (7.7)             | (0) 0               | 16 (16.7)      |

<div style=\"page-break-after: always\"></div>

| Systeim Organ Class Preferred Term              | Cohort I (N=59) n (%)   | Cohort IIA (N=4) n (%)   | Cohort IIB (N=13) (%)I   | Cohort III (N=20) (%)   | Total (N=96) (%) I   |
|-------------------------------------------------|-------------------------|--------------------------|--------------------------|-------------------------|----------------------|
| Nervous system disorders                        | 21 (35.6)               | 2 (50)                   | 1 (7.7)                  | 0 (0)                   | 24 (25)              |
| Dizziness                                       | 6 (10.2)                | 0 (0)                    | 0 (0)                    | 0 (0)                   | 6 (6.3)              |
| Headache                                        | 10 (16.9)               | 2 (50)                   | 0 (0)                    | 0 (0)                   | 12 (12.5)            |
| Psychiatric disorders                           | 8 (13.6)                | 1 (25)                   | 1 (7.7)                  | 0 (0)                   | 10 (10.4)            |
| Anger                                           | (0) 0                   | 1 (25)                   | (0)0                     | (0) 0                   | 1 (1)                |
| Mood swings                                     | (0) 0                   | 1 (25)                   | (0)0                     | (0) 0                   | 1 (1)                |
| Reproductive system and breast disorders        | 8 (13.6)                | (0) 0                    | (0) 0                    | 1 (5)                   | 9 (9.4)              |
| Respiratory, thoracic and mediastinal disorders | 32 (54.2)               | 2 (50)                   | 7 (53.8)                 | 10 (50)                 | 51 (53.1)            |
| Cough                                           | 28 (47.5)               | 2 (50)                   | 5 (38.5)                 | 6 (30)                  | 41 (42.7)            |
| Nasal congestion                                | 14 (23.7)               | 1 (25)                   | 3 (23.1)                 | 2 (10)                  | 20 (20.8)            |
| Oropharyngeal pain                              | 13 (22)                 | 0 (0)                    | 3 (23.1)                 | 0 (0)                   | 16 (16.7)            |
| Rhinorrhoea                                     | 19 (32.2)               | 0 (0)                    | 3 (23.1)                 | 4 (20)                  | 26 (27.1)            |
| Wheezing                                        | 6 (10.2)                | 1 (25)                   | 1 (7.7)                  | 2 (10)                  | 10 (10.4)            |
| Skin and subcutaneous tissue disorders          | 26 (44.1)               | 1 (25)                   | 2 (15.4)                 | 6 (30)                  | 35 (36.5)            |
| Eezema                                          | 1 (1.7)                 | 0 (0)                    | 2 (15.4)                 | 1 (5)                   | 4 (4.2)              |
| Macule                                          | 1 (1.7)                 | (0) 0                    | (0) 0                    | 2 (10)                  | 3 (3.1)              |
| Rash                                            | 2 (3.4)                 | 1 (25)                   | 1 (7.7)                  | 0 (0)                   | 4 (4.2)              |
| Rash generalised                                | (0) 0                   | (0) 0                    | 2 (15.4)                 | (0) 0                   | 2 (2.1)              |

Grade 3 or greater clinical AEs were reported by 15.6% of patients and 10.4% reported Grade 3 or greater AEs that mapped to the Infections and Infestations SOC. Additional AEs reported between Weeks 24 and 48 included bacterial pneumonia, abdominal pain, iron deficiency anaemia, decreased weight, failure to thrive, bacterial sepsis, convulsion, reversible posterior leucoencephalopathy syndrome, erythema, conjunctival hyperaemia, periorbital cellulitis and influenza-like illness.

## AEs of special interest

The applicant's database was explored for a series of pre-defined AEs of special interest based on what is known about raltegravir and also other ARTs. Some highlighted cases include AEs of rash (none of these events was reported as Grade 3 or 4 or serious) and psychiatric disorders (by week 48 of the study, 10.4% of final dose patients reported psychiatric disorders including one reported Grade 3 AEs considered possibly related to raltegravir by the investigator).

## Serious adverse event/deaths/other significant events

One patient in the All Treated population had a SAE of pneumonia resulting in death by the data cut-off date. The investigator determined that Grade 5 bilateral pneumonia was not related to study raltegravir

By Week 24, 13 Final Dose patients had reported 16 SAEs including pyrexia, acute renal failure, metrorrhagia, pneumonia (7 events), infection, asthma, suicidal behaviour (2 events), respiratory tract infection and allergic dermatitis. Also, there was one SAE of depression in an All Treated patient. The category with the highest frequency of SAEs was Infections and Infestations (9 patients [9.4%]), all in

Isentress Assessment report

<div style=\"page-break-after: always\"></div>

Cohort I. The only SAE considered related to study raltegravir by the investigator was the case of allergic dermatitis.

At Week 48 there had been 21 SAEs reported by 14 (14.6%) patients in the Final Dose population. The 5 additional SAEs that occurred between Weeks 24 and 48 included pneumonia, failure to thrive, convulsion, anaemia and periorbital cellulitis. These events were not considered related to study raltegravir by the investigator. There were no additional reports of SAEs by All Treated patients between Weeks 24 and 48. Between Week 48 and the data cut-off date, there were 11 additional SAEs including pain in extremity, pneumonia, oesophagitis, anaemia (3 events for the same patient), cachexia, pyrexia, Mycobacterium Avium complex infection, bacterial pneumonia and respiratory distress. These events were not considered related to study raltegravir by the investigators. Three additional All Treated patients reported SAEs after Week 48 and all events were considered not related to study raltegravir by the investigators.

There were three pregnancies reported of which one resulted in intra-uterine fetal death not considered to be treatment-related.

## Laboratory findings

## Final Dose, Weeks 0-24

Laboratory AEs were reported by 75% of Final Dose patients. Most were Grade 1 and 2. The most frequently reported included decreased neutrophil count (21% [20/96]), which ranged from Grades 1 to 4, decreased non-fasting blood glucose (20% [19/96]), which were primarily Grade 1, and decreased blood sodium (18% [17/96]), which were primarily Grade 1 events. There were two laboratory SAEs of which one was considered drug-related by the investigator. Grade 3 or greater laboratory AEs were reported in 13.5% of which one patient in Cohort III had AEs considered to be drug-related (increased ALT and AST; see below).

## Final Dose, Weeks 0-48

Laboratory AEs were reported by 84.4% of Final Dose patients. Most laboratory AEs were Grades 1 and 2 and the most frequently reported were similar to those observed at Week 24. Additional Grade 3 or greater laboratory AEs reported by Final Dose patients between Weeks 24 and 48 included decreased haemoglobin, increased blood glucose, increased blood bilirubin, increased ALT (5 events) and increased AST (8 events). The most frequently reported event was decreased neutrophil count (8.3%).

Three All Treated patients reported Grade 3 or greater laboratory adverse events considered possibly drug-related by the investigator. One patient in Cohort IIB had increased low density lipoprotein by Week 24. One in Cohort I had decreased neutrophil count by Week 24 and one on Cohort IIA had drug-related decreased neutrophil count (2 events, both possibly related) by Week 48.

## Alanine aminotransferase (ALT)

There were two Final Dose patients who had a Grade 3 or greater serum ALT increase that represented a worsening from baseline. One considered possibly related to study raltegravir and one considered not related to raltegravir by the investigators.

## Aspartate aminotransferase (AST)

One patient in Cohort IIB reported increased AST (highest report: Grade 4) that was considered not related to study raltegravir by the investigator.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

No patients from the Final Dose or All Treated population discontinued due to a clinical or laboratory AE up to the data cut-off date.

## 2.6.1. Discussion on clinical safety

The safety data do not give rise to any new or major concerns. In particular, the choice of Final Dose was not in any way limited by issues of safety when administered as either the adult tablet or chewable tablet formulation in combination with OBR.

All the adverse reactions reported in the clinical trial have been included in the Summary of Product Characteristics.

In the view of the safety profile of the chewable tablets, the CHMP considers that the PSUR cycle of this medicinal product should remain unchanged.

## 2.6.2. Conclusions on the clinical safety

The safety data in the claimed paediatric indication do not give rise to any new safety findings in the paediatric population in comparison to the adult population. In addition, no specific safety concerns in the paediatric population were identified in the data submitted with the present application. Therefore, the CHMP concludes that the safety profile of raltegravir in the proposed indication is acceptable.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

No update of the pharmacovigilance system was submitted with the present application.

## Risk Management Plan

The applicant submitted a risk management plan, which included an update of the existing risk minimisation plan to reflect the extension of the marketing authorisation to children from 2 to 18 years and the new chewable tablets. The risk management plan was reviewed and agreed by the CHMP.

Given the limited number of patients enrolled in the paediatric 022, the CHMP requested the applicant to collect additional data in children aged 2 to &lt;6 years to provide further data on the adequacy of the recommended posology with particular reference to the threshold value of Ctrough ~ 45nM.

Since the start of the procedure, the applicant has submitted an updated version of the RMP (v9, 17 August 2012) with the procedure (EMEA/H/C/860/II/37) which included the changes related to the present application.

## 2.8. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

No full user consultation with target patient groups on the package leaflet for the 25mg chewable tablets has been performed on the basis of a bridging report making reference to the 100mg chewable tablets. The bridging report submitted by the applicant has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

Raltegravir has been shown to be effective in adults. However, the in-vitro and in-vivo data have clearly underlined the importance of administering it as part of a total ART regimen that preferably includes at least two other agents predicted to be active.

In line with the CHMP guideline on the clinical development of medicinal products for the treatment of HIV infection (Doc. Ref. EMEA/CPMP/EWP/633/02), based on the identification of suitable dose regimens and the expectation that PK/PD relationships are the same in children as in adults, an extrapolation of efficacy data obtained in adults to children may be accepted.

Data from study 022 lead to recommendation to use a fixed dose of the adult formulation 400 BID when body weight is ≥ 25 kg in children aged 6 to 18 years and a weight based regimen of 6mg/kg, to maximum dose 300 mg, twice daily, of the chewable tablets when body weight is ≥ 12 kg in children aged 2 to 12 years. These dose recommendations were considered adequate by the CHMP.

Based on the Ctrough threshold of ~45 nM, the CHMP was of the opinion that the intensive sampling data and the CV% values from study P022 support these dosing recommendations. Indeed, based on the Ctrough threshold of ~45 nM, the intensive sampling data and the CV% values support the dosing recommendations, regardless of the fact that GM Ctrough derived from intensive sampling drifts downwards with decreasing age. The individual numbers with Ctrough &lt; 45 nM were 0-2 per age group/dose cohort. Focusing on the Ctrough comparisons, neither the intensive nor the (calculationcorrected) sparse sampling Ctrough suggest that there would be a risk of values below 33 (or even 45) nM when using the chewable tablets in children aged 2 to &lt;6 years of age compared with other age group / dose Cohort.

Study P022 has been designed in line with the recommendations of the CHMP guideline on the clinical development of medicinal products for the treatment of HIV infection (Doc. Ref.

EMEA/CPMP/EWP/633/02). Therefore efficacy wasn't a primary endpoint; however, the overall virological and immunological response rates in study P022 were satisfactory.

## Uncertainty in the knowledge about the beneficial effects

Despite the supportive PK/PD data and the overall good virological and immunological response rates, this design of study P022 presents some limitations (i.e. open label trial, small number of patients enrolled, etc…).

The Committee was of the opinion that these limitations are inherent to the settings of this PK study and the provision of limited data in paediatric cohorts is considered acceptable for an antiretroviral agent that has been shown to be efficacious in adults as it is the case for raltegravir.

However, given the limited number of patients enrolled in this paediatric study, the CHMP requested that the applicant collects additional information in children aged 2 to &lt;6 years of age to provide further data on the adequacy of the recommended posology with particular reference to the threshold value of Ctrough ~ 45nM.

<div style=\"page-break-after: always\"></div>

## Risks

## Unfavourable effects

The safety data in the claimed paediatric indication do not give rise to any new safety findings in the paediatric population in comparison to the adult population. In addition, no specific safety concerns in the paediatric population were identified in the data submitted with the present application. Therefore, the CHMP concludes that the safety profile of raltegravir in the proposed indication is acceptable.

## Uncertainty in the knowledge about the unfavourable effects

Despite the overall safety profile similar to adults and the absence of new findings specific to the paediatric population, the sample size was expectedly too small to draw definite conclusions.

## Benefit-risk balance

As stated in the CHMP guideline on the clinical development of medicinal products for the treatment of HIV infection (Doc. Ref. EMEA/CPMP/EWP/633/02), provided that reliable pharmacokinetic data support robust dose recommendations, an extrapolation of efficacy data obtained in adults to children may be accepted.

Data from study 022 supports the use of a fixed dose of the adult formulation 400 BID when body weight is ≥ 25 kg in children aged 6 to 18 years and a weight based regimen of 6mg/kg, to maximum dose 300 mg, twice daily, of the chewable tablets when body weight is ≥ 12 kg in children aged 2 to 12 years.

Based on the Ctrough threshold of ~45 nM, the intensive sampling data and the CV% values from study P022 support these dosing recommendations.

Therefore, the CHMP concludes that extrapolation from adult to the paediatric population covered by the proposed indication is acceptable.

This is supported by the overall satisfactory virological and immunological response rates in Study P022.

In addition, the safety data in the claimed paediatric indication do not give rise to any new safety findings in the paediatric population in comparison to the adult population. No specific safety concerns in the paediatric population were identified in the data submitted with the present application.

As a consequence, the CHMP concluded that the benefit /risk balance is favourable for use of raltegravir with a fixed dose of the adult formulation 400 BID when body weight is ≥ 25 kg in children aged 6 to 18 years and a weight based regimen of 6mg/kg, to maximum dose 300 mg, twice daily, of the chewable tablets when body weight is ≥ 12 kg in children aged 2 to 12 years.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by majority that the risk/benefit balance of the extension of Marketing Authorisation for Isentress chewable tablets 25 mg and 100 mg in the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral

<div style=\"page-break-after: always\"></div>

therapy (ART)-experienced paediatric patients from the age of 2 years is favourable and therefore recommends the granting of the marketing authorisation subject to the current conditions below.

In addition, the CHMP considers by consensus the following variation acceptable and recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variations requested   | Variations requested                                                                                                 | Type   |
|------------------------|----------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                | Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Update the section 4.1 of the SmPC for the existing 400mg film-coated tablet with the new paediatric indication (adolescents and children from the age of 6 years) and introduce consequential changes to all sections of the SmPC for the existing 400mg film-coated tablet (except Sections 1 and 3), Annexes II, IIIA and IIIB.

Changes to the product information were introduced in line with the QRD template.

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the Marketing Authorisation

## Risk Management System

The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the marketing authorisation, is in place and functioning before and whilst the product is on the market.

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the Risk Management Plan (RMP) presented in Module 1.8.2 of the marketing authorisation and any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted:

- When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
- at the request of the EMA

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

Not applicable

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan (P/95/2009) and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

<div style=\"page-break-after: always\"></div>

Divergent positions to the majority recommendation on the extension of MA are appended to this report.

<div style=\"page-break-after: always\"></div>

## 5. Appendix

## Divergent Positions

The undersigned members of CHMP did not agree with the CHMP's opinion recommending the variation of the marketing authorisation of Isentress.

The reasons for divergent opinion were as follows:

Balancing the benefit of raltegravir as a treatment alternative in very small children, and the risks related to uncertainties about adequate drug exposure, we do not consider that the chewable tablet regimen for patients aged 2-6 years is approvable. The data on C12h and AUC from detailed and sparse sampling suggest that the recommended posology could result in inadequate exposures to raltegravir compared to adults.

Failure with a raltegravir-based regimen is very often accompanied by high level raltegravir resistance, as well as resistance to cytidine analogues. The consequences of virological failure due to suboptimal dosing in small children, in terms of remaining treatment options, would be of considerable relevance.

From ages 6 years and upwards the adult formulation can be used.

London, 13 December 2012

…………………………………………

…………………………………………

Pierre Demolis

Kristina Dunder

…………………………………………

…………………………………………

Harald Enzmann

Jan Mueller Berghaus